{{noteTA|G1 = ME|G2=LS}}
{{Infobox medical condition (new)
| name            = 多發性硬化症
| image           = MS Demyelinisation CD68 10xv2.jpg
| caption         = 多發性硬化症造成的脫髓鞘性病變。 {{tsl|en|CD68|CD68}}將病灶處的[[巨噬细胞|巨噬细胞]]染色。 
| field           = [[神經內科|神經內科]]
| synonyms        = 瀰漫性硬化症、瀰漫性腦脊髓炎
| symptoms        = 複視、單側[[視力受損|視力受損]]、肌肉無力、[[感受|感覺]]受損、協調障礙<ref name=NIH2015/>
| complications   = 
| onset           = 20–50歲<ref name=Milo2010/>
| duration        = 慢性<ref name=NIH2015/>
| causes          = 未知<ref name=Nak2012/>
| risks           = 
| diagnosis       = 基於症狀和醫學檢驗<ref name=Tsang2011/>
| differential    = 
| prevention      = 
| treatment       = 藥物、物理治療<ref name=NIH2015/>
| medication      = 
| prognosis       = [[预期寿命|預期餘命]]小於5-10年<ref name="pmid18970977"/>
| frequency       = 200萬分之一（2015）<ref name=GBD2015Pre>{{cite journal | author = GBD 2015 Disease and Injury Incidence and Prevalence Collaborators | title = Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 | journal = Lancet | volume = 388 | issue = 10053 | pages = 1545–1602 | date = October 2016 | pmid = 27733282 | pmc = 5055577 | doi = 10.1016/S0140-6736(16)31678-6 }}</ref>
| deaths          = 18,900（2015）<ref name=GBD2015De>{{cite journal | author = GBD 2015 Mortality and Causes of Death Collaborators | title = Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 | journal = Lancet | volume = 388 | issue = 10053 | pages = 1459–1544 | date = October 2016 | pmid = 27733281 | pmc = 5388903 | doi = 10.1016/s0140-6736(16)31012-1 }}</ref>
}}
<!-- 定義和症狀 -->
'''多發性硬化症'''（Multiple sclerosis，'''MS'''）是一種{{tsl|en|demyelinating disease|脫髓鞘性神經病變|}}，患者[[脑|腦]]或[[脊髓|脊髓]]中的[[神經元|神經細胞]]表面的絕緣物質（即[[髓磷脂|髓鞘]]）受到破壞<ref name=NIH2015>{{cite web|title=NINDS Multiple Sclerosis Information Page|url=http://www.ninds.nih.gov/disorders/multiple_sclerosis/multiple_sclerosis.htm|website=National Institute of Neurological Disorders and Stroke|access-date=2016-03-06|date=2015-11-19|deadurl=yes|archive-url=https://web.archive.org/web/20160213025406/http://www.ninds.nih.gov/disorders/multiple_sclerosis/multiple_sclerosis.htm|archive-date=2016-02-13}}</ref>，神經系統的訊息傳遞受損，導致一系列可能發生的症狀，影響患者的活動、心智、甚至精神狀態<ref name="pmid18970977">{{cite journal | vauthors = Compston A, Coles A |author1-link=Alastair Compston | title = Multiple sclerosis | journal = Lancet | volume = 372 | issue = 9648 | pages = 1502–17 | date = October 2008 | pmid = 18970977 | doi = 10.1016/S0140-6736(08)61620-7 }}</ref><ref name="pmid11955556">{{cite journal | vauthors = Compston A, Coles A | title = Multiple sclerosis | journal = Lancet | volume = 359 | issue = 9313 | pages = 1221–31 | date = April 2002 | pmid = 11955556 | doi = 10.1016/S0140-6736(02)08220-X }}</ref><ref>{{cite book|title=Bradley's neurology in clinical practice.|year=2012|publisher=Elsevier/Saunders|location=Philadelphia, PA|isbn=1-4377-0434-4|edition=6th|vauthors=Murray ED, Buttner EA, Price BH |veditors=Daroff R, Fenichel G, Jankovic J, Mazziotta J |chapter=Depression and Psychosis in Neurological Practice}}</ref>。這些症狀可能包括複視、單側[[視力受損|視力受損]]、肌肉無力、感覺遲鈍，或協調障礙<ref name=NIH2015/>。多發性硬化症的病情多變，患者的症狀可能反覆發作，也可能持續加劇<ref name="pmid8780061">{{cite journal | vauthors = Lublin FD, Reingold SC | author1-link=Fred D. Lublin | title = Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis | journal = Neurology | volume = 46 | issue = 4 | pages = 907–11 | date = April 1996 | pmid = 8780061 | doi = 10.1212/WNL.46.4.907 }}</ref>。在每次發作之間，症狀有可能完全消失，但永久性的神經損傷仍然存在，這在病情嚴重的患者特別明顯<ref name="pmid8780061"/>。

<!--病因、病生理學和診斷 -->
雖然具體的成因不明，但多發性硬化症的機制可能為髓鞘[[自體免疫性疾病|受到免疫系統破壞]]或生成髓鞘的細胞發生問題<ref name=Nak2012>{{cite journal | vauthors = Nakahara J, Maeda M, Aiso S, Suzuki N | title = Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy | journal = Clinical Reviews in Allergy & Immunology | volume = 42 | issue = 1 | pages = 26–34 | date = February 2012 | pmid = 22189514 | doi = 10.1007/s12016-011-8287-6 }}</ref>，可能的原因包括遺傳與環境因素，例如受[[病毒|病毒]]感染的刺激而引發自體免疫反應<ref name="pmid11955556"/><ref name="pmid17444504">{{cite journal | vauthors = Ascherio A, Munger KL | title = Environmental risk factors for multiple sclerosis. Part I: the role of infection | journal = Annals of Neurology | volume = 61 | issue = 4 | pages = 288–99 | date = April 2007 | pmid = 17444504 | doi = 10.1002/ana.21117 }}</ref>。多發性硬化症的診斷需藉助臨床表現和相關的影像學證據支持<ref name=Tsang2011>{{cite journal | vauthors = Tsang BK, Macdonell R | title = Multiple sclerosis- diagnosis, management and prognosis | journal = Australian Family Physician | volume = 40 | issue = 12 | pages = 948–55 | date = December 2011 | pmid = 22146321 }}</ref>。

<!--治療與預後 -->
目前尚無根治多發性硬化症的方法<ref name=NIH2015/>，現有的治療多為改善患者發作後的日常功能，並預防疾病再度復發<ref name="pmid11955556"/>。[[物理治療|物理治療]]則能改善患者的功能<ref name=NIH2015/>。許多人會尋求[[替代疗法|替代疗法]]，儘管其療效缺乏證據支持<ref name="pmid16420779">{{cite journal | vauthors = Huntley A | title = A review of the evidence for efficacy of complementary and alternative medicines in MS | journal = International MS Journal | volume = 13 | issue = 1 | pages = 5–12, 4 | date = January 2006 | pmid = 16420779 | doi =  }}</ref>。多發性硬化症的長期預後很難預測，通常女性、較年輕發作、反覆復發緩解（relapsing-remitting）和一開始發作次數較少的患者有較佳的預後<ref name="pmid8017890">{{cite journal | vauthors = Weinshenker BG | title = Natural history of multiple sclerosis | journal = Annals of Neurology | volume = 36 Suppl | issue = Suppl | pages = S6-11 | year = 1994 | pmid = 8017890 | doi = 10.1002/ana.410360704 }}</ref>。患者的預期壽命較一般人少5至10年<ref name="pmid18970977"/>。

<!--流行病學和歷史  -->
多發性硬化症是最常見的[[中樞神經系統|中樞神經系統]]{{tsl|en|immune disorder|免疫疾病|}}<ref name="pmid24746689">{{cite journal | vauthors = Berer K, Krishnamoorthy G | title = Microbial view of central nervous system autoimmunity | journal = FEBS Letters | volume = 588 | issue = 22 | pages = 4207–13 | date = November 2014 | pmid = 24746689 | doi = 10.1016/j.febslet.2014.04.007 }}</ref>。2015年全球約有230萬人罹患此病，但不同地區和族群的盛行率差異極大<ref name=GBD2015Pre/><ref name=Atlas2008>{{cite book |author=World Health Organization |title=Atlas: Multiple Sclerosis Resources in the World 2008 |publisher=World Health Organization |location=Geneva |year=2008 |pages=15–16 |isbn=92-4-156375-3 |url=http://whqlibdoc.who.int/publications/2008/9789241563758_eng.pdf |deadurl=no |archive-url=https://web.archive.org/web/20131004215703/http://whqlibdoc.who.int/publications/2008/9789241563758_eng.pdf |archive-date=2013-10-04  }}</ref>；同年，約有18,900人死於多發性硬化症，相較於1990年的12,000人高出許多<ref name=GBD2015De/><ref name=GDB2013>{{cite journal | vauthors =  | title = Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 | journal = Lancet | volume = 385 | issue = 9963 | pages = 117–71 | date = January 2015 | pmid = 25530442 | pmc = 4340604 | doi = 10.1016/S0140-6736(14)61682-2 }}</ref>。多發性硬化症通常在20到50歲之間發病，女性的發生率為男性的2倍<ref name=Milo2010>{{cite journal | vauthors = Milo R, Kahana E | title = Multiple sclerosis: geoepidemiology, genetics and the environment | journal = Autoimmunity Reviews | volume = 9 | issue = 5 | pages = A387-94 | date = March 2010 | pmid = 19932200 | doi = 10.1016/j.autrev.2009.11.010 }}</ref>。1868年，[[让-马丁·沙可|让-马丁·沙可]]首次描述了多發性硬化症<ref name="Charcot1"/>，意指大腦白質和脊髓中有許多疤痕（sclerae，可理解為現在所稱的斑塊或病灶）<ref name="Charcot1">{{cite journal | vauthors = Clanet M | title = Jean-Martin Charcot. 1825 to 1893 | journal = International MS Journal | volume = 15 | issue = 2 | pages = 59–61 | date = June 2008 | pmid = 18782501 | url = http://www.msforum.net/Site/ViewPDF/ViewPDF.aspx?ArticleID=E80DC748-5048-4BD2-9393-18BCAE0A1514&doctype=Article | format = PDF }}<br />* {{cite journal |author=Charcot, J. |year=1868 |title=Histologie de la sclerose en plaques |journal=Gazette des hopitaux, Paris |volume=41 |pages=554–5 }}</ref>。多種新的治療與診斷方法都正在研究當中<ref name="pmid19597083">{{cite journal | vauthors = Cohen JA | title = Emerging therapies for relapsing multiple sclerosis | journal = Archives of Neurology | volume = 66 | issue = 7 | pages = 821–8 | date = July 2009 | pmid = 19597083 | doi = 10.1001/archneurol.2009.104 }}</ref>。
{{TOC limit|3}}

==症狀==
[[File:Symptoms_of_multiple_sclerosis_zh-tw.svg|thumb]]

多發性硬化症患者可能出現任何神經學症狀，其中[[自主神经系统|自主神經]]、視覺、運動和感覺問題最常出現<ref name="pmid18970977"/>。確切的症狀則依患者病灶的實際位置而異，可能有{{tsl|en|hypoesthesia|感覺喪失}}或{{tsl|en|paresthesia|感覺異常}}（如刺痛感或麻木等）、肌肉無力、{{tsl|en|blurred vision|視力模糊}}<ref>{{cite web|url=http://www.webmd.com/multiple-sclerosis/|title=MS Signs|last=|first=|date=|website={{tsl|en|Webmd||Webmd}}|access-date=2016-10-07|deadurl=no|archive-url=https://web.archive.org/web/20160930181511/http://www.webmd.com/multiple-sclerosis/|archive-date=2016-09-30}}</ref>、[[阵挛性状态|反射增強]]、[[痙攣|痙攣]]或運動困難、無法維持協調與平衡（[[共济失调|共济失调]]）、{{tsl|en|dysarthria|構音困難|發音困難}}或[[吞嚥障礙|吞嚥障礙]]、視覺問題（如[[眼球震颤|眼球震颤]]、{{tsl|en|optic neuritis|視神經炎}}或[[复视|复视]]）、[[疲勞|疲勞]]、[[疼痛|急性]]或[[慢性疼痛|慢性疼痛]]、膀胱與腸胃蠕動問題等等<ref name="pmid18970977"/>，思考障礙或情緒問題（如[[重度抑郁症|憂鬱症]]或[[假性延髓情绪|情緒不穩]]）也很常見<ref name="pmid18970977"/>。{{tsl|en|Uhthoff's phenomenon|烏托夫現象}}（Uhthoff's phenomenon，溫度較高時症狀較嚴重）和{{tsl|en|Lhermitte's sign|萊爾米特徵候}}（Lhermitte's sign，即把頸部前彎時會感到一股電流傳到背上）則是多發性硬化症典型的徵候<ref name="pmid18970977"/>。{{tsl|en|expanded disability status scale|扩展残疾状态量表}}（EDSS）是用來量化疾病嚴重度和患者失能程度的主要指標，其他指標如{{tsl|en|multiple sclerosis functional composite|多發性硬化症功能複合量表}}也越來越常用於研究中<ref>{{cite journal | vauthors = Kurtzke JF | author-link=John F. Kurtzke | title = Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) | journal = Neurology | volume = 33 | issue = 11 | pages = 1444–52 | date = November 1983 | pmid = 6685237 | doi = 10.1212/WNL.33.11.1444 }}</ref><ref name="pmid10467378">{{cite journal | vauthors = Amato MP, Ponziani G | title = Quantification of impairment in MS: discussion of the scales in use | journal = Multiple Sclerosis | volume = 5 | issue = 4 | pages = 216–9 | date = August 1999 | pmid = 10467378 | doi = 10.1191/135245899678846113 }}</ref><ref name="pmid12356200">{{cite journal | vauthors = Rudick RA, Cutter G, Reingold S | title = The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials | journal = Multiple Sclerosis | volume = 8 | issue = 5 | pages = 359–65 | date = October 2002 | pmid = 12356200 | doi = 10.1191/1352458502ms845oa }}</ref>。

約85%的患者一開始僅出現{{tsl|en|clinically isolated syndrome|臨床單一症候群|臨床單一症狀}}（CIS，即發生一次疑似多發性硬化症的發作），幾天後45%的患者未出現運動或感覺問題、20%有{{tsl|en|optic neuritis|視神經炎}}、10%有和[[腦幹|腦幹]]相關的症狀，剩下的25%則有超過一種前述的問題<ref name=Tsang2011/>。症狀最初通常以兩種形式出現：患者可能會有幾次持續數天到數個月的急性惡化並隨後改善（85%）；也可能緩慢逐漸惡化而沒有任何好轉的跡象（10–15%）<ref name=Milo2010/>；病程也可能混合上述兩種形式<ref name="pmid8780061"/>，或一開始會發作和改善，但之後卻轉為持續惡化<ref name=Milo2010/>。症狀的發作通常沒有徵兆，因此難以預測，但很少一年超過兩次<ref name="pmid18970977"/>。然而有些患者的發作會受特定因素刺激，因此在春夏較常出現<ref name="pmid16804331">{{cite journal | vauthors = Tataru N, Vidal C, Decavel P, Berger E, Rumbach L | title = Limited impact of the summer heat wave in France (2003) on hospital admissions and relapses for multiple sclerosis | journal = Neuroepidemiology | volume = 27 | issue = 1 | pages = 28–32 | year = 2006 | pmid = 16804331 | doi = 10.1159/000094233 }}</ref>。同樣地，病毒感染（如[[普通感冒|感冒]]、[[流行性感冒|流行性感冒]]或[[腸胃炎|腸胃炎]]）也會增加風險<ref name="pmid18970977"/>，[[壓力_(醫學)|壓力]]也可能引起疾病發作<ref name="pmid17439878">{{cite journal | vauthors = Heesen C, Mohr DC, Huitinga I, Bergh FT, Gaab J, Otte C, Gold SM | title = Stress regulation in multiple sclerosis: current issues and concepts | journal = Multiple Sclerosis | volume = 13 | issue = 2 | pages = 143–8 | date = March 2007 | pmid = 17439878 | doi = 10.1177/1352458506070772 }}</ref>。 患有多發性硬化症的婦女在懷孕後會較少發作，但生產後的頭幾個月發作風險會增加<ref name="pmid18970977"/>；整體而言，懷孕不會影響長期預後<ref name="pmid18970977"/>。目前已知許多因素都不會影響多發性硬化症的復發率，包括[[接種疫苗|接種疫苗]]、[[母乳哺育|餵乳]]<ref name="pmid18970977"/>、身體創傷<ref name="pmid11205361">{{cite journal | vauthors = Martinelli V | title = Trauma, stress and multiple sclerosis | journal = Neurological Sciences | volume = 21 | issue = 4 Suppl 2 | pages = S849-52 | year = 2000 | pmid = 11205361 | doi = 10.1007/s100720070024 | url = http://link.springer-ny.com/link/service/journals/10072/bibs/00214%20Suppl%202/0021S849.htm }}{{dead link|date=September 2017 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>和{{Le|烏托夫現象|Uhthoff's phenomenon}}（Uhthoff's phenomenon）<ref name="pmid16804331"/>。

==病因==
多發性硬化症的病因未明，但一般相信是由遺傳和環境因素（如感染）共同造成<ref name="pmid18970977"/>。有許多理論試圖將臨床資料和假說相結合，但仍沒有確切的答案。雖然目前已知有若干環境風險因子是能透過人為改善的，但消除此類環境因子是否能預防多發性硬化症還有待進一步研究<ref name="pmid15556803"/>。

===地理===
多發性硬化症在緯度較高的地區較常出現<ref name="pmid18970977"/><ref name="pmid18606967"/>，但此分佈也有例外。某些住在高緯地區的種族盛行率較低，例如[[萨米人|萨米人]]、[[美洲原住民|美洲原住民]]、加拿大[[胡特尔派|胡特爾人]]、紐西蘭[[毛利人|毛利人]]<ref name="pmid12127652">{{cite journal | vauthors = Pugliatti M, Sotgiu S, Rosati G | title = The worldwide prevalence of multiple sclerosis | journal = Clinical Neurology and Neurosurgery | volume = 104 | issue = 3 | pages = 182–91 | date = July 2002 | pmid = 12127652 | doi = 10.1016/S0303-8467(02)00036-7 }}</ref>和加拿大[[因纽特人|因纽特人]]<ref name=Milo2010/>；某些住在赤道附近的族群盛行率則相對較低，例如{{tsl|en|Sardinians|薩丁尼亞人}}<ref name=Milo2010/>、[[西西里岛|西西里人]]<ref>{{cite journal | vauthors = Grimaldi LM, Salemi G, Grimaldi G, Rizzo A, Marziolo R, Lo Presti C, Maimone D, Savettieri G | title = High incidence and increasing prevalence of MS in Enna (Sicily), southern Italy | journal = Neurology | volume = 57 | issue = 10 | pages = 1891–3 | date = November 2001 | pmid = 11723283 | doi = 10.1212/wnl.57.10.1891 }}</ref>、[[巴勒斯坦人|巴勒斯坦人]]和[[帕西人|帕西人]]<ref name="pmid12127652"/>。造成此種地理分布的原因未知<ref name=Milo2010/>，雖然目前南北分布差異逐漸縮小<ref name="pmid18606967"/>，但到2010年為止仍然存在<ref name=Milo2010/>。

多發性硬化症在北歐族群較常見<ref name="pmid18970977"/>，這反映了此類高風險族群的全球分布狀況<ref name=Milo2010/>，部分學者認為這和高緯地區陽光照射較少導致體內[[维生素D|維生素D]]較少有關<ref name="pmid17492755"/><ref name="pmid20494325">{{cite journal | vauthors = Ascherio A, Munger KL, Simon KC | title = Vitamin D and multiple sclerosis | journal = The Lancet. Neurology | volume = 9 | issue = 6 | pages = 599–612 | date = June 2010 | pmid = 20494325 | doi = 10.1016/S1474-4422(10)70086-7 }}</ref><ref>{{cite journal | vauthors = Koch MW, Metz LM, Agrawal SM, Yong VW | title = Environmental factors and their regulation of immunity in multiple sclerosis | journal = Journal of the Neurological Sciences | volume = 324 | issue = 1–2 | pages = 10–6 | date = January 2013 | pmid = 23154080 | doi = 10.1016/j.jns.2012.10.021 }}</ref>。出生季節和多發性硬化症的關聯支持前項假說，北半球十一月出生的人相較於五月出生的人較容易發生多發性硬化症<ref name="pmid19897699">{{cite journal | vauthors = Kulie T, Groff A, Redmer J, Hounshell J, Schrager S | title = Vitamin D: an evidence-based review | journal = Journal of the American Board of Family Medicine | volume = 22 | issue = 6 | pages = 698–706 | year = 2009 | pmid = 19897699 | doi = 10.3122/jabfm.2009.06.090037 }}</ref>。兒童時期的環境因子可能也有重要的影響，一些研究發現15歲前移居其他地方居住的孩童適用於移居處的發病率；但若15歲以後才搬家，則風險與其家鄉較為相近<ref name="pmid18970977"/><ref name="pmid15556803"/>。其他證據則顯示15歲以後移居仍會對罹病風險產生影響<ref name="pmid18970977"/>。

===遺傳===
[[File:HLA.svg|thumb]]
普遍不認為多發性硬化症是一種[[遺傳|遺傳]]疾病，但一些[[遗传学|遺傳變異]]可能會增加罹病風險<ref name="pmid14747002">{{cite journal | vauthors = Dyment DA, Ebers GC, Sadovnick AD | title = Genetics of multiple sclerosis | journal = The Lancet. Neurology | volume = 3 | issue = 2 | pages = 104–10 | date = February 2004 | pmid = 14747002 | doi = 10.1016/S1474-4422(03)00663-X }}</ref>，有些此類的基因在微膠細胞中似乎有超乎預期的表現量<ref name="SkeneGrant2016">{{cite journal | vauthors = Skene NG, Grant SG | title = Identification of Vulnerable Cell Types in Major Brain Disorders Using Single Cell Transcriptomes and Expression Weighted Cell Type Enrichment | journal = Frontiers in Neuroscience | volume = 10 | pages = 16 | year = 2016 | pmid = 26858593 | doi = 10.3389/fnins.2016.00016 }}</ref>。患者的親屬罹患多發性硬化症的機率較一般人高，血緣關係親近者風險更高<ref name="pmid11955556"/>；同卵雙胞胎的另一人約有30%的罹病率，而異卵雙胞胎則只有5%，手足更只有2.5%，同父異母或同母異父的手足機率更低<ref name="pmid18970977"/><ref name="pmid11955556"/><ref>{{cite journal | vauthors = Hassan-Smith G, Douglas MR | title = Epidemiology and diagnosis of multiple sclerosis | journal = British Journal of Hospital Medicine | volume = 72 | issue = 10 | pages = M146-51 | date = October 2011 | pmid = 22041658 }}</ref>。若雙親都有多發性硬化症，則孩童的發生率為一般人的十倍<ref name=Milo2010/>。此外，特定族裔的盛行率也比較高<ref name="pmid11603614">{{cite journal | vauthors = Rosati G | title = The prevalence of multiple sclerosis in the world: an update | journal = Neurological Sciences | volume = 22 | issue = 2 | pages = 117–39 | date = April 2001 | pmid = 11603614 | doi = 10.1007/s100720170011 }}</ref>。

目前已發現許多和多發性硬化症有關的[[基因|基因]]，其中就包括了[[人類白細胞抗原|人類白細胞抗原]]（HLA），這是一群在第六染色體上作為[[主要组织相容性复合体|主要組織相容性複合體]]（MHC）的蛋白質<ref name="pmid18970977"/>。 HLA和多發性硬化症之間的關聯最初在1980年代發現<ref name="pmid21247752">{{cite journal | vauthors = Baranzini SE | title = Revealing the genetic basis of multiple sclerosis: are we there yet? | journal = Current Opinion in Genetics & Development | volume = 21 | issue = 3 | pages = 317–24 | date = June 2011 | pmid = 21247752 | pmc = 3105160 | doi = 10.1016/j.gde.2010.12.006 }}</ref>，現在該區域已證實和其他自體免疫疾病（如[[1型糖尿病|1型糖尿病]]和[[全身性紅斑狼瘡|全身性紅斑狼瘡]]）有關<ref name="pmid21247752"/>。目前已知和多發性硬化症最有關的MHC[[等位基因|等位基因]]為{{tsl|en|HLA-DR15||DR15}}和{{tsl|en|HLA-DQ6||DQ6}}<ref name="pmid18970977"/>，另有些基因座如[[HLA-C|HLA-C554]]和{{tsl|en|HLA-DRB1||HLA-DRB1}}*11似乎對多發性硬化症有保護作用<ref name="pmid18970977"/>。整體而言，HLA的改變對多發性硬化症貢獻了20%至60%的{{tsl|en|genetic predisposition|遺傳傾向|}}<ref name="pmid21247752"/>。透過現代的遺傳學方法（如[[全基因组关联分析|全基因組關聯分析]]），科學家已發現其他至少12個HLA基因座以外的基因可能會增加多發性硬化症的罹病率<ref name="pmid21247752"/>。

===感染===
科學家曾提出多種[[微生物|微生物]]可能會誘發多發性硬化症，但沒有一種獲得證實<ref name="pmid11955556"/>。早年就移居到世界上的其他地方會改變之後罹患多發性硬化症的風險<ref name="pmid17444504"/>，針對這種現象的一種解釋是移居地可能會有原住居處少見的感染症<ref name="pmid17444504"/>；其他解釋則有[[卫生假说|衛生假說]]和盛行假說。衛生假說認為在生命早年暴露於特定的感染源能增強個體的保護力，若長大後才接觸那些病源則會造成疾病<ref name="pmid18970977"/>。盛行假說則認為多發性硬化症是由盛行地區某種感染源造成，但多數受感染的人沒有症狀，只有少數個案在數年後才真的造成脫鞘病變<ref name="pmid17444504"/><ref name="pmid8269393"/>。目前衛生假說較盛行假說獲得更多支持<ref name="pmid17444504"/>。

多數多發性硬化症的患者腦和[[腦脊液|腦脊髓液]]中含有{{tsl|en|oligoclonal band|寡克隆條帶|}}，部分研究者認為這可能是病毒感染的證據，該現象也會出現在某些人類病毒性脫鞘性{{tsl|en|encephalomyelitis|腦脊髓炎|}}和動物的病毒性脫鞘性疾病<ref name="pmid15721830">{{cite journal | vauthors = Gilden DH | title = Infectious causes of multiple sclerosis | journal = The Lancet. Neurology | volume = 4 | issue = 3 | pages = 195–202 | date = March 2005 | pmid = 15721830 | doi = 10.1016/S1474-4422(05)01017-3 }}</ref>。目前懷疑[[疱疹病毒科|人類皰疹疹病毒]]是最可能的感染源。未曾被[[人類疱疹病毒第四型|EB病毒]]感染的人罹患多發性硬化症的機率較低，但在成人早年受感染的人比更年輕就被感染的人有更高的罹病風險<ref name="pmid18970977"/><ref name="pmid17444504"/>。有些學者認為此項假說和衛生假說抵觸，因為未受感染的人可能有較好的衛生教育<ref name="pmid17444504"/>；其他學者則相信兩者並不衝突，因為相較於衛生假說中的早期感染源，患者是在生命較後期才接觸到刺激多發性硬化症的病源菌<ref name="pmid18970977"/>。其他相關的病毒感染可能還包括[[麻疹|麻疹]]、[[流行性腮腺炎|腮腺炎]]和[[風疹|德國麻疹]]<ref name="pmid18970977"/>。

===其它===
目前已知[[吸菸|吸菸]]是多發性硬化症的一個獨立風險因子<ref name="pmid17492755"/>。壓力也可能會增加罹病風險，但相關的證據較為薄弱<ref name="pmid15556803"/>。職業毒物暴露（主要為有機溶劑）的影響也曾受評估，但沒有明確的結果<ref name="pmid15556803"/>。以往的研究對[[疫苗接種|疫苗接種]]做過因果分析，但多數沒有找到關聯性<ref name="pmid15556803"/>。其他可能的風險因子（如[[飲食_(營養學)|飲食]]和[[激素|賀爾蒙]]攝取）也曾被科學家檢視，但這些因素和多發性硬化症間的關係都較薄弱且缺乏說服力<ref name="pmid17492755"/>。多發性硬化症的患者罹患[[痛风|痛風]]的比率較低，血中的[[尿酸|尿酸]]濃度也較低；因此有假說認為尿酸對多發性硬化症有保護作用，但目前對於尿酸扮演的角色仍屬未知<ref name="pmid18219824">{{cite journal | vauthors = Spitsin S, Koprowski H | title = Role of uric acid in multiple sclerosis | journal = Current Topics in Microbiology and Immunology | volume = 318 | issue =  | pages = 325–42 | year = 2008 | pmid = 18219824 | doi = 10.1007/978-3-540-73677-6_13 }}</ref>。

==病生理學==
[[File:Multiple_Sclerosis.png|thumb]]
[[File:Neuron.png|thumb]]
多發性硬化症發生的三個重要特徵包含出現[[中樞神經系統|中樞神經系統]]病灶、發炎反應，以及[[髓磷脂|髓鞘破壞]]等。關於上述特徵如何出現，以及這些機轉如何導致臨床症狀，目前尚未完全了解<ref name="pmid18970977"/>。目前相信{{tsl|en|Cholesterol crystal|膽固醇結晶}}會導致髓鞘破壞，並加強發炎反應<ref name="pmid29439228">{{cite journal | vauthors=Chen Y, Popko B | title=Cholesterol crystals impede nerve repair | journal= [[科学_(期刊)|Science]] | volume=359 | issue=6376 | pages=635–635 | year=2018 | doi= 10.1126/science.aar7369 | PMID = 29439228 }}</ref><ref name="pmid29301957">{{cite journal | vauthors=Cantuti-Castelvetri L, Fitzner D, Bosch-Queralt M, Weil MT, Su M, Sen P, Ruhwedel T, Mitkovski M, Trendelenburg G, Lütjohann D, Möbius W, Simons M | title=Defective cholesterol clearance limits remyelination in the aged central nervous system | journal= [[科学_(期刊)|Science]] | volume=359 | issue=6376 | pages=684–688 | year=2018 | doi= 10.1126/science.aan4183 | PMID = 29301957 }}</ref>。多發性硬化症目前認為是一種{{tsl|en|Immune-mediated inflammatory diseases|免疫介導性發炎疾病|免疫發炎}}引起的疾病<ref name="pmid11955556"/>，意即疾病乃是因個體的免疫系統引起的發炎反應破壞了神經系統<ref name="pmid11955556"/>。可能是遺傳或其他尚未證實的環境因子使然<ref name="pmid11955556"/>。
===病灶===
[[Image:MS_Demyelinisation_KB_10x.jpg|thumb]]
多發性硬化症會造成受侵犯的神經病灶處產生疤痕，並以此得名。本疾病最常進犯[[视神经|視神經]]、[[腦幹|腦幹]]、[[基底核|基底核]]、[[脊髓|脊髓]]，以及[[侧脑室|側腦室]]周圍的[[白質|白質]]<ref name="pmid18970977"/>。白質主要由神經纖維構成，負責傳遞[[灰质|灰質]]腦區間的信息。多發性硬化症較少侵犯[[周邊神經系統|周邊神經系統]]<ref name="pmid11955556"/>。

更精確一點來說，多發性硬化症會造成[[寡突膠質細胞|寡突膠質細胞]]的喪失。寡突膠質細胞會產生和維持包覆神經纖維的[[髓鞘|髓鞘]]，幫助[[动作电位|動作電位]]的傳導<ref name="pmid18970977"/>；若寡突膠質細胞受到進犯，可能會導致髓鞘消失或變薄，甚至使神經元的[[軸突|軸突]]受損退化。髓鞘消失後，神經元的傳導效率會下降<ref name="pmid11955556" />，因此寡突膠細胞會啟動{{tsl|en|remyelination|再髓鞘化|}}的程序修復髓鞘。這種修復現象可以疾病初期看到，但寡突膠的修復能力並無法完全重建髓鞘<ref name="pmid17531860">{{cite journal|title=Remyelination in multiple sclerosis|journal=International Review of Neurobiology|issue=|doi=10.1016/S0074-7742(07)79026-8|year=2007|volume=79|pages=589–620|pmid=17531860|vauthors=Chari DM}}</ref>。若髓鞘反覆受損，再髓鞘化的效能會逐漸下降，最後導致受損軸突周圍堆滿了疤痕狀的斑塊<ref name="pmid17531860"/>。這些疤痕會導致多發性硬化症的症狀。在症狀發作時，[[核磁共振成像|磁振照影]]（MRI）時常會顯示腦部出現十幾個新斑塊<ref name="pmid18970977"/>。這種現象可能代表患者腦部其實存在有大量的病灶，但因為神經的自癒功能，使患者平時沒有出現明顯症狀<ref name="pmid18970977"/>。另外，病灶處也會因為神經損傷而導致{{tsl|en|astrocytosis|星狀細胞增多|星狀細胞異常增多}}<ref name="pmid18970977"/>。目前有許多關於多發性硬化症的{{tsl|en|pathophysiology of multiple sclerosis|多發性硬化症的病生理學|病理特徵}}已經被描述<ref name="pmid17351524">{{cite journal | vauthors = Pittock SJ, Lucchinetti CF | title = The pathology of MS: new insights and potential clinical applications | journal = The Neurologist | volume = 13 | issue = 2 | pages = 45–56 | date = March 2007 | pmid = 17351524 | doi = 10.1097/01.nrl.0000253065.31662.37 }}</ref>。

===發炎反應===
除脫髓鞘現象外，[[炎症|發炎反應]]也是多發性硬化症的重要體徵之一。[[T细胞|T細胞]]在多發性硬化症的發炎反應中扮演重要角色<ref name="pmid11955556"/>，平時中樞神經系統會受到[[血腦屏障|血腦障壁]]保護，一旦這層屏障受到破壞，T細胞就會進到中樞神經，將髓鞘視為外來物進行攻擊，這些攻擊自身的淋巴細胞又稱自體反應性淋巴球（autoreactive lymphocytes）<ref name="pmid18970977"/>。髓鞘遭受攻擊後會誘發免疫反應的產生，使免疫細胞釋放[[细胞因子|細胞激素]]和[[抗体|抗體]]，擴大發炎反應。持續擴大的發炎反應可能會導致血腦障壁的瓦解，進而出現一系列神經受損的現象，例如神經[[水肿|水腫]]、[[巨噬細胞|巨噬細胞]]活化、細胞激素釋放，以及出現許多遭受破壞的蛋白質<ref name="pmid11955556" />。發炎反應也會透過至少三種途徑影響訊息的傳導<ref name="pmid18970977" />，發炎介質會阻滯周圍正常神經的信息傳遞，另外髓鞘的破壞也會減少神經信息的傳遞效率<ref name="pmid18970977" />。

===血腦障壁===
[[血腦屏障|血腦障壁]]是中樞神經系統血管外一層防止防止血液中的物質進入腦脊髓的屏障，同時也能阻擋T細胞進入<!-- <ref name="pmid11955556"/> -->。但如果中樞神經遭到病毒或細菌感染時，血腦障壁的通透性會增大<!-- <ref name="pmid11955556"/> -->。感染消退後，血腦障壁會自行修復，但當初跑進來的T細胞會殘留在腦中<ref name="pmid11955556"/>。[[钆|钆]]是一種沒有辦法穿透正常血腦障壁的元素，因此钆增強磁振造影（gadolinium-enhanced MRI）可以用於檢測血腦障壁瓦解與否<ref name="pmid23088946">{{cite journal | vauthors = Ferré JC, Shiroishi MS, Law M | title = Advanced techniques using contrast media in neuroimaging | journal = Magnetic Resonance Imaging Clinics of North America | volume = 20 | issue = 4 | pages = 699–713 | date = November 2012 | pmid = 23088946 | pmc = 3479680 | doi = 10.1016/j.mric.2012.07.007 }}</ref>。

==診斷==
[[File:Monthly_multiple_sclerosis_anim_cropped_no_text.gif|thumb]][[File:MSMRIMark.png|thumb]]
臨床症狀是診斷多發性硬化症的重要依據，配合[[醫學影像|醫學影像]]和醫學檢驗可以輔助診斷<ref name=Tsang2011/>。但症狀常與其他疾病類似，造成診斷較為困難，特別是在疾病初期<ref name="pmid18970977"/><ref name="pmid11794488">{{cite journal|title=The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes|url=http://link.springer-ny.com/link/service/journals/10072/bibs/122%20Suppl%202000/122%20Suppl%2020S98.htm|date=November 2001|journal=Neurological Sciences|issue=Suppl 2|doi=10.1007/s100720100044|volume=22 Suppl 2|pages=S98-102|pmid=11794488|vauthors=Trojano M, Paolicelli D}}{{dead link|date=September 2017|bot=InternetArchiveBot|fix-attempted=yes}}</ref>。{{tsl|en|McDonald criteria|麥克唐納診斷標準|}}（McDonald criteria）是目前最常使用的診斷工具，該標準收錄了臨床、檢驗，以及放射醫學的證據<ref name=Atlas2008/>。{{tsl|en|Schumacher criteria|舒馬克診斷標準|舒馬克}}和{{tsl|en|Poser criteria|波色診斷標準|}}是過去常用的診斷標準，但已被麥氏標準取代<ref name="pmid15177763">{{cite journal | vauthors = Poser CM, Brinar VV | title = Diagnostic criteria for multiple sclerosis: an historical review | journal = Clinical Neurology and Neurosurgery | volume = 106 | issue = 3 | pages = 147–58 | date = June 2004 | pmid = 15177763 | doi = 10.1016/j.clineuro.2004.02.004 }}</ref>。惟2010年的麥氏標準在部分疾病的診斷描述上，與其他疾病重疊（如{{Le|泛視神經脊髓疾病|neuromyelitis optica spectrum disorders}}等），因此2016年，歐洲多發性硬化症核磁共振影像學會連線（European Magnetic Resonance Imaging in Multiple Sclerosis，MAGNIMS）提出了MAGNIMS共識，加入影像學的判斷，為麥式標準的內容進行修訂<ref>{{Cite journal|title=Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria|author=|url=https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(17)30470-2/abstract|last=Cohen|first=Jeffrey A.|last2=Reingold|first2=Stephen C.|date=2018-02-01|journal=The Lancet Neurology|issue=2|doi=10.1016/S1474-4422(17)30470-2|others=|year=|volume=17|page=|pages=162–173|language=|issn=1474-4422|pmid=29275977|last3=Weinshenker|first3=Brian G.|last4=Waubant|first4=Emmanuelle|last5=Vukusic|first5=Sandra|last6=Uitdehaag|first6=Bernard M. J.|last7=Trojano|first7=Maria|last8=Traboulsee|first8=Anthony L.|last9=Tintoré|first9=Mar}}</ref>。

若患者有多次特異性較高的事件發作，可能直接透過臨床證據即可診斷多發性硬化症<ref name="pmid11456302"/>。但若僅有發作過一次，則必須進行其他測試來輔助診斷。最常見的工具有[[神經影像學|神經影像學]]、腦脊髓液分析，以及[[事件相关电位|誘發電位測試]]。[[核磁共振成像|核磁共振]]影像可以顯示腦部喊脊隨脫髓鞘的區域，以及斑塊等病灶。靜脈輸注含[[钆|钆]]的{{tsl|en|contrast agent|顯影劑|}}可以標定活躍斑塊，且也可以顯影無症狀性的斑塊病灶<ref name="pmid11456302"/><ref name="pmid18256986">{{cite journal | vauthors = Rashid W, Miller DH | title = Recent advances in neuroimaging of multiple sclerosis | journal = Seminars in Neurology | volume = 28 | issue = 1 | pages = 46–55 | date = February 2008 | pmid = 18256986 | doi = 10.1055/s-2007-1019127 }}</ref>。腦脊髓液分析可以顯示中樞神經系統是否存在慢性發炎，需透過[[腰椎穿刺|腰椎穿刺]]採檢取得。技術員會將腦脊液進行[[电泳|電泳]]，檢視電泳膠片上是否帶有IgG的{{tsl|en|oligoclonal band|寡克隆條帶|}}（oligoclonal band），75–85%的多發性硬化症患者的腦脊液分析可以找到特徵<ref name="pmid11456302"/><ref name="pmid16945427">{{cite journal | vauthors = Link H, Huang YM | title = Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness | journal = Journal of Neuroimmunology | volume = 180 | issue = 1–2 | pages = 17–28 | date = November 2006 | pmid = 16945427 | doi = 10.1016/j.jneuroim.2006.07.006 }}</ref>。此外，由於脫髓鞘現象，患者的[[視神經|視神經]]和[[感覺神經元|感覺神經]]對於刺激的敏感度也會下降，這些現象可以透過視神經和感覺神經的[[事件相关电位|誘發電位]]偵測而得<ref name="pmid10802774">{{cite journal | vauthors = Gronseth GS, Ashman EJ | title = Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology | journal = Neurology | volume = 54 | issue = 9 | pages = 1720–5 | date = May 2000 | pmid = 10802774 | doi = 10.1212/WNL.54.9.1720 }}</ref>。

上述的診斷方式皆屬於非侵入性的診斷方式<ref name="pmid18970977"/>，但有時必須透過[[驗屍|遺體解剖]]和病灶的[[組織活檢|組織活檢]]才能確診<ref name="pmid11456302">{{cite journal | vauthors = McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS | author1-link=W. Ian McDonald | author16-link=Jerry Wolinsky | title = Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis | journal = Annals of Neurology | volume = 50 | issue = 1 | pages = 121–7 | date = July 2001 | pmid = 11456302 | doi = 10.1002/ana.1032 }}</ref><ref name="pmid16283615">{{cite journal | vauthors = Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS | title = Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria" | journal = Annals of Neurology | volume = 58 | issue = 6 | pages = 840–6 | date = December 2005 | pmid = 16283615 | doi = 10.1002/ana.20703 }}</ref>。截至目前為止，尚無單一檢驗（包括組織活檢）可以確診多發性硬化症<ref>{{cite journal | vauthors = Rovira À | title = Diagnosis of Multiple Sclerosis. | journal = Journal of the Belgian Society of Radiology | volume = 101(S1)| pages = 12 | date = November 2017 | doi = 10.5334/jbr-btr.1426}}</ref>。

==分型==
截至2013年為止，{{tsl|en|National Multiple Sclerosis Society|美國國家多發性硬化症學會|}}（National Multiple Sclerosis Society）和{{tsl|en|Multiple Sclerosis International Federation|國際多發性硬化症聯合會|}}（Multiple Sclerosis International Federation）已描述了四種分型。分型有利於從過去病史推斷為來的預後，且對未來的治療策略也有重要意義<ref name="NMSS-types-2013-vs-1996">{{cite web| url = http://www.nationalmssociety.org/NationalMSSociety/media/MSNational/Charts-Graphics/new_MSdiseasecourses_table.pdf| title = Changes in multiple sclerosis disease-course (or "type") descriptions| access-date = 2017-08-21| author = {{tsl|en|National Multiple Sclerosis Society||National Multiple Sclerosis Society}}| quote = NEW COURSE ADDED: Clinically Isolated Syndrome (CIS)...COURSE ELIMINATED: Progressive Relapsing (PRMS).| deadurl = no| archive-url = https://web.archive.org/web/20160803214243/http://www.nationalmssociety.org/NationalMSSociety/media/MSNational/Charts-Graphics/new_MSdiseasecourses_table.pdf| archive-date = 2016-08-03}}</ref><ref name=Lublin>{{cite web| url = http://www.neurology.org/content/83/3/278.full | title = Defining the clinical course of multiple sclerosis, The 2013 revisions |vauthors=Lublin FD, etal | date = 2014-07-15| doi = 10.1212/WNL.0000000000000560}}</ref><ref name="NMSS-types">{{cite web| url = http://www.nationalmssociety.org/What-is-MS/Types-of-MS| title = Types of MS| access-date = 2017-08-21| author = {{tsl|en|National Multiple Sclerosis Society||National Multiple Sclerosis Society}}| quote = Four disease courses have been identified in multiple sclerosis: clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS).| deadurl = no| archive-url = https://web.archive.org/web/20170707222351/https://www.nationalmssociety.org/What-is-MS/Types-of-MS| archive-date = 2017-07-07}}</ref>：

# 臨床單一症候群（Clinically isolated syndrome，CIS）
# 復發緩解型多發性硬化症（Relapsing-remitting MS，RRMS）
# 原發進行性多發性硬化症（Primary progressive MS，PPMS）
# 續發進行性多發性硬化症（Secondary progressive MS，SPMS）

復發緩解型（RRMS）多發性硬化症中最常見的一型，占所有首次發作病患的80%左右<ref name="pmid18970977" />。此類患者在單次發作後，會進入數月到數年的{{tsl|en|remission (medicine)|緩解 (醫學)|緩解期}}，在此期間病患的症狀會相對穩定，但在之後會無預期性地復發。每次發作後所造成的神經功能缺損可能會幾乎緩解，但也有約40%的病人會有{{tsl|en|sequelae|後遺症|}}，且發作時間越久，發生後遺症的機會越大<ref name="pmid18970977"/><ref name=Tsang2011/>。由於此類患者在發作後會緩解，有時又被視為「良性多發性硬化症」（benign MS）<ref name="pmid18219812">{{cite journal | vauthors = Pittock SJ, Rodriguez M | title = Benign multiple sclerosis: a distinct clinical entity with therapeutic implications | journal = Current Topics in Microbiology and Immunology | volume = 318 | issue =  | pages = 1–17 | year = 2008 | pmid = 18219812 | doi = 10.1007/978-3-540-73677-6_1 | isbn = 978-3-540-73676-9 | series = Current Topics in Microbiology and Immunology }}</ref>，但長期下來，患者的神經損傷仍然會累積，最終導致神經功能退化<ref name="pmid18970977"/>。另一方面，所謂「{{tsl|en|malignant multiple sclerosis|惡性多發性硬化症|}}」則是描述在短期即會造成神經功能明顯減退的類型<ref>{{cite book|author=Feinstein A|title=The clinical neuropsychiatry of multiple sclerosis|year=2007|publisher=Cambridge University Press|location=Cambridge|isbn=052185234X|page=20|edition=2nd}}</ref>。臨床單一症候群（CIS）是描述病人發生一次疑似脫髓鞘的症狀，但尚未符合多發性硬化症的診斷標準<ref name="pmid18970977"/><ref name="pmid15847841">{{cite journal | vauthors = Miller D, Barkhof F, Montalban X, Thompson A, Filippi M | title = Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis | journal = The Lancet. Neurology | volume = 4 | issue = 5 | pages = 281–8 | date = May 2005 | pmid = 15847841 | doi = 10.1016/S1474-4422(05)70071-5 }}</ref>。約有30-70%的CIS最後會進展為多發性硬化症，而RRMS大多也會以CIS最為其初始表現<ref name="pmid15847841"/>。

原發進行性多發性硬化症（PPMS）約占多發性硬化症患者的10–20%，此類患者在初始發作後，症狀即會不斷惡化，完全不會緩解或改善<ref name="pmid8780061" /><ref name=Tsang2011/><ref name="pmid17884680">{{cite journal | vauthors = Miller DH, Leary SM | title = Primary-progressive multiple sclerosis | journal = The Lancet. Neurology | volume = 6 | issue = 10 | pages = 903–12 | date = October 2007 | pmid = 17884680 | doi = 10.1016/S1474-4422(07)70243-0 }}</ref>。此類病人會較復發緩解型晚發病。復發緩解型和續發進行性大約都是在40歲左右發病<ref name="pmid18970977"/>。雖然此類病人的表現與RRMS有極大差異，但期病程進展速度其實大致相同<ref>{{Cite journal|title=Will the real multiple sclerosis please stand up?|author=|url=https://www.nature.com/articles/nrn3275|last=Geurts|first=Jeroen J. G.|last2=Jan van Minnen|date=2012-07|journal=Nature Reviews Neuroscience|issue=7|doi=10.1038/nrn3275|others=|year=|volume=13|page=|pages=507–514|language=|issn=1471-0048|pmid=|last3=Zamponi|first3=Gerald W.|last4=Stys|first4=Peter K.}}</ref>。

續發進行性（SPMS）常以RRMS作為初始表現，約有65%初始診斷為RRMS的病患為SPMS。此類型的特點是在每次發作之後，神經功能都會有所減退，且之間沒有明顯的緩解期<ref name="pmid18970977"/><ref name="pmid8780061"/>。此類患者的症狀偶爾會再發或輕微緩解<ref name="pmid8780061"/>。一般來說，RRMS會進展到SPMS之間常會間隔19年左右<ref name="pmid16545751">{{cite journal | vauthors = Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M | title = Secondary progressive multiple sclerosis: current knowledge and future challenges | journal = The Lancet. Neurology | volume = 5 | issue = 4 | pages = 343–54 | date = April 2006 | pmid = 16545751 | doi = 10.1016/S1474-4422(06)70410-0 }}</ref>。

除了上述四種類型之外，還有多種疑似多發性硬化症的亞型也已被描述，這些亞型被統稱為{{tsl|en|Idiopathic inflammatory demyelinating diseases|特發性發炎性脫髓鞘病|}}。如{{tsl|en|Devic's disease|視神經脊髓炎|}}、{{tsl|en|Diffuse myelinoclastic sclerosis|瀰漫性脫髓鞘硬化症|}}、{{tsl|en|Balo concentric sclerosis|同心圓性硬化症|}}、{{tsl|en|Marburg multiple sclerosis|馬爾堡多發性硬化症|}}。目前關於這些疾病是否真的屬於多發性硬化症仍有爭議<ref name="pmid15727225">{{cite journal | vauthors = Stadelmann C, Brück W | title = Lessons from the neuropathology of atypical forms of multiple sclerosis | journal = Neurological Sciences | volume = 25 Suppl 4 | issue = Suppl 4 | pages = S319-22 | date = November 2004 | pmid = 15727225 | doi = 10.1007/s10072-004-0333-1 }}</ref>。兒童多發性患者的表現與成人不同，其進展到進行期（progressive stage）的速度較慢<ref name="pmid18970977"/>，不過仍然會在一般成人達到進行期的平均年齡之前<ref name="pmid18970977"/>。

==治療==
雖然目前無法治癒多發性硬化症，但部分療法已被證實能有效控制疾病。治療的目標為恢復患者的功能、預防再次發作和失能。一般會建議有發作過一次並有兩處以上MRI病灶的患者開始使用藥物介入<ref name=Neurology2018>{{cite journal|last1=Rae-Grant|first1=Alexander|last2=Day|first2=Gregory S.|last3=Marrie|first3=Ruth Ann|last4=Rabinstein|first4=Alejandro|last5=Cree|first5=Bruce A.C.|last6=Gronseth|first6=Gary S.|last7=Haboubi|first7=Michael|last8=Halper|first8=June|last9=Hosey|first9=Jonathan P.|last10=Jones|first10=David E.|last11=Lisak|first11=Robert|last12=Pelletier|first12=Daniel|last13=Potrebic|first13=Sonja|last14=Sitcov|first14=Cynthia|last15=Sommers|first15=Rick|last16=Stachowiak|first16=Julie|last17=Getchius|first17=Thomas S.D.|last18=Merillat|first18=Shannon A.|last19=Pringsheim|first19=Tamara|title=Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis|journal=Neurology|date=2018-04-23|volume=90|issue=17|pages=777–788|doi=10.1212/WNL.0000000000005347}}</ref>。就如同其他許多藥物一樣，多發性硬化症的治療可能會帶來一些[[不良反应_(医学)|副作用]]。人們也不斷嘗試[[替代医学|另類療法]]，即便這些療法的效果缺乏證據支持<ref name="pmid16420779" />。

===急性發作===
在患者症狀發作時，通常會[[靜脈注射|靜脈注射]]高劑量[[皮質類固醇|類固醇]]（如{{tsl|en|methylprednisolone|甲基培尼皮質醇|}}）<ref name="pmid18970977"/>，口服類固醇似乎也有類似的效果和安全性<ref>{{cite journal | vauthors = Burton JM, O'Connor PW, Hohol M, Beyene J | title = Oral versus intravenous steroids for treatment of relapses in multiple sclerosis | journal = The Cochrane Database of Systematic Reviews | volume = 12 | pages = CD006921 | date = December 2012 | pmid = 23235634 | doi = 10.1002/14651858.CD006921.pub3 }}</ref>。整體而言，雖然類固醇能暫時緩解症狀，但似乎對長期預後沒有顯著影響<ref name="RCOP_acute">{{cite book|author=The National Collaborating Centre for Chronic Conditions|title=Multiple sclerosis : national clinical guideline for diagnosis and management in primary and secondary care|year=2004|publisher=Royal College of Physicians|location=London|isbn=1-86016-182-0|pages=54–57|url=https://www.ncbi.nlm.nih.gov/books/NBK48919/pdf/TOC.pdf|access-date=2013-02-06|format=pdf|pmid=21290636}}</ref>。而對類固醇沒有反應的嚴重發作則可考慮以{{tsl|en|plasmapheresis|血漿置換術|}}治療<ref name="pmid18970977"/>。

===疾病調節藥物治療===

==== 復發緩解型多發性硬化症 ====
截至2017年，已有十種藥物核准用於復發緩解型多發性硬化症的疾病調節，這些疾病分別為{{tsl|en|interferon beta-1a|干擾素β-1a|}}、{{tsl|en|interferon beta-1b|干擾素β-1b|}}、{{tsl|en|glatiramer acetate|醋酸格拉替美|}}（glatiramer acetate）、[[米托蒽醌|米托蒽醌]]（mitoxantrone）、{{tsl|en|natalizumab|那他珠單抗|}}（natalizumab）、{{tsl|en|fingolimod|芬戈莫德|}}（fingolimod）、{{tsl|en|teriflunomide|特立氟胺|}}（teriflunomide）<ref name=He2016>{{cite journal | vauthors = He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L | title = Teriflunomide for multiple sclerosis | journal = The Cochrane Database of Systematic Reviews | volume = 3 | pages = CD009882 | date = March 2016 | pmid = 27003123 | doi = 10.1002/14651858.CD009882.pub3 }}</ref><ref name="Aubagio">{{cite press release|title=FDA approves new multiple sclerosis treatment Aubagio|date=2012-09-12|publisher=US FDA|url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=202992|access-date=2017-09-22|deadurl=yes|archive-url=https://web.archive.org/web/20170130222628/http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202992|archive-date=2017-01-30}}</ref>、{{tsl|en|dimethyl fumarate|富馬酸二甲酯|}}（dimethyl fumarate）<ref name=fumarate>{{cite press release|url=http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqId=1801165|title=Biogen Idec’s TECFIDERA™ (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multiple Sclerosis|publisher=Biogen Idec|date=2013-03-27|access-date=2013-06-04|deadurl=yes|archive-url=https://web.archive.org/web/20130512021453/http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqId=1801165|archive-date=2013-05-12}}</ref>、{{tsl|en|alemtuzumab|阿侖單抗|}}（alemtuzumab）<ref>{{cite news|title=FDA Approves Lemtrada|url=https://www.drugs.com/newdrugs/fda-approves-lemtrada-alemtuzumab-relapsing-forms-multiple-sclerosis-4110.html|date=2013-11-14|agency=Biogen Idec Press Release|deadurl=no|archive-url=https://web.archive.org/web/20141119014548/http://www.drugs.com/newdrugs/fda-approves-lemtrada-alemtuzumab-relapsing-forms-multiple-sclerosis-4110.html|archive-date=2014-11-19}}</ref><ref>{{cite journal | vauthors = Riera R, Porfírio GJ, Torloni MR | title = Alemtuzumab for multiple sclerosis | journal = The Cochrane Database of Systematic Reviews | volume = 4 | pages = CD011203 | date = April 2016 | pmid = 27082500 | doi = 10.1002/14651858.CD011203.pub2 }}</ref>，和{{tsl|en|ocrelizumab|奥美珠单抗|}}（ocrelizumab）<ref>{{cite news|title=FDA Ocrevus approval|url=https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm549325.htm|date=2017-03-29|agency=FDA Press Release|deadurl=no|archive-url=https://web.archive.org/web/20170403185536/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm549325.htm|archive-date=2017-04-03}}</ref>。

截至2012年，藥物治療的成本效益仍然未明<ref>{{cite journal | vauthors = Manouchehrinia A, Constantinescu CS | title = Cost-effectiveness of disease-modifying therapies in multiple sclerosis | journal = Current Neurology and Neuroscience Reports | volume = 12 | issue = 5 | pages = 592–600 | date = October 2012 | pmid = 22782520 | doi = 10.1007/s11910-012-0291-6 }}</ref>。2017年3月，[[美国食品药品监督管理局|美国食品药品监督管理局]]（FDA）核准{{tsl|en|ocrelizumab|奥美珠单抗|}}用於治療復發緩解型，該藥物為一種抗{{tsl|en|CD20||CD20}}的{{tsl|en|Humanized antibody|人源化抗體|人源化}}[[单克隆抗体|單株抗體]]<ref name=STATapproval>{{cite news |title=After 40-year odyssey, first drug for aggressive MS wins FDA approval |url=https://www.statnews.com/2017/03/28/multiple-sclerosis-ms-drug-ocrelizumab/ |date=2017-03-28 |author=Ron Winslow |publisher=STAT |deadurl=no |archive-url=https://web.archive.org/web/20170401151407/https://www.statnews.com/2017/03/28/multiple-sclerosis-ms-drug-ocrelizumab/ |archive-date=2017-04-01  }}</ref><ref name=FDAlabel2017>{{cite web|title=Ocrelizumab label|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf|publisher=FDA|access-date=2017-04-01|date=March 2017|deadurl=no|archive-url=https://web.archive.org/web/20170401232405/https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf|archive-date=2017-04-01}} See [http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761053 FDA index page for BLA 761053] {{webarchive|url=https://web.archive.org/web/20170401233016/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761053 |date=2017-04-01 }} for updates.</ref>，仍有多項{{tsl|en|Phases of clinical research|臨床試驗階段|第四期臨床試驗}}進行中<ref name=FDABLAapproval>{{cite web|title=BLA Approval Letter|url=https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/761053Orig1s000ltr.pdf|publisher=FDA|date=2017-03-28|deadurl=no|archive-url=https://web.archive.org/web/20170402081250/https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/761053Orig1s000ltr.pdf|archive-date=2017-04-02}}</ref>。

減少發作次數對於復發換解型的病程有一定的效果<ref name=He2016 />。目前的第一線治療為干擾素和格拉替美<ref name=Tsang2011/>，兩者大約皆可減少復發機率30%左右<ref name=Hassan2011>{{cite journal | vauthors = Hassan-Smith G, Douglas MR | title = Management and prognosis of multiple sclerosis | journal = British Journal of Hospital Medicine | volume = 72 | issue = 11 | pages = M174-6 | date = November 2011 | pmid = 22082979 }}</ref>，且成人跟兒童的小果大致相仿<ref name="pmid22642799">{{cite journal | vauthors = Johnston J, So TY | title = First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview | journal = Drugs | volume = 72 | issue = 9 | pages = 1195–211 | date = June 2012 | pmid = 22642799 | doi = 10.2165/11634010-000000000-00000 }}</ref>。提早開始長期治療的療程可以改善預後，且安全性無虞<ref name="pmid21205679">{{cite journal | vauthors = Freedman MS | title = Long-term follow-up of clinical trials of multiple sclerosis therapies | journal = Neurology | volume = 76 | issue = 1 Suppl 1 | pages = S26-34 | date = January 2011 | pmid = 21205679 | doi = 10.1212/WNL.0b013e318205051d }}</ref><ref name="pmid22284996">{{cite journal | vauthors = Qizilbash N, Mendez I, Sanchez-de la Rosa R | title = Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis | journal = Clinical Therapeutics | volume = 34 | issue = 1 | pages = 159–176.e5 | date = January 2012 | pmid = 22284996 | doi = 10.1016/j.clinthera.2011.12.006 }}</ref>。那他珠單抗降低復發機會的效果，比起第一線治療更加顯著。但因為擁有一些副作用，因此做為第二線療法，用於對其他療法反應不佳<ref name=Tsang2011/>，或擁有嚴重不良反應的病人<ref name=Hassan2011/>。米托蒽醌的使用受制於嚴重的不良反應，因此目前歸為第三線治療，用於對前兩線治療反應不佳的病人<ref name=Tsang2011/>。臨床單一症候群（CIS）用[[干扰素|干擾素]]治療可以減少病人進展為多發性硬化症的機率<ref name="pmid18970977"/><ref name="pmid21205678">{{cite journal | vauthors = Bates D | title = Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials | journal = Neurology | volume = 76 | issue = 1 Suppl 1 | pages = S14-25 | date = January 2011 | pmid = 21205678 | doi = 10.1212/WNL.0b013e3182050388 }}</ref>。截至2011年，芬戈莫德、特立氟胺，以及富馬酸二甲酯等較新藥物的效果尚未明朗<ref name="pmid22014437"/>。

截至2017年，儘管[[利妥昔單抗|利妥昔單抗]]（rituximab）尚未核准用於多發性硬化症的治療，但臨床上仍{{Le|仿單標示外使用|Off-label use|常用於治療}}復發換解型多發性硬化症<ref name=McGinley2017rev>{{cite journal | vauthors = McGinley MP, Moss BP, Cohen JA | title = Safety of monoclonal antibodies for the treatment of multiple sclerosis | journal = Expert Opinion on Drug Safety | volume = 16 | issue = 1 | pages = 89–100 | date = January 2017 | pmid = 27756172 | doi = 10.1080/14740338.2017.1250881 }}</ref>。

==== 進行性多發性硬化症 ====
2017年以前，[[利妥昔單抗|利妥昔單抗]]（rituximab）廣泛被作為原發進行性多發性硬化症的仿單標示外治療<ref name=McGinley2017rev/>。2017年3月，[[美国食品药品监督管理局|美國食品藥品監督管理局]]（FDA）核准了{{tsl|en|ocrelizumab|奥美珠单抗|}}（ocrelizumab），使之成為第一個核准用於治療原發進行性多發性硬化症的藥物<ref name=STATapproval/><ref name=FDAlabel2017/>，美國FDA並要求對該藥物進行若干{{tsl|en|Phases of clinical research|臨床試驗分期|第四期}}臨床試驗<ref name=FDABLAapproval/>。

{{As of|2011}}，[[米托蒽醌|米托蒽醌]]（mitoxantrone）是唯一一種核准用於治療續發進行性多發性硬化症的藥物<ref name="BopeKellerman2011">{{cite book|author1=Edward T. Bope|author2=Rick D. Kellerman|title=Conn's Current Therapy 2012: Expert Consult – Online and Print|url=https://books.google.com/books?id=pyKjGU5JdqQC&pg=PT662|date=2011-12-22|publisher=Elsevier Health Sciences|isbn=1-4557-0738-4|pages=662– }}</ref>。在這些患者中，目前的證據暫時支持蒽醌 I能適度緩解疾病惡化，並減少兩年內發作的機率<ref name=CochMit2013>{{cite journal | vauthors = Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G | title = Mitoxantrone for multiple sclerosis | journal = The Cochrane Database of Systematic Reviews | volume = 5 | issue = 5 | pages = CD002127 | date = May 2013 | pmid = 23728638 | doi = 10.1002/14651858.CD002127.pub3 }}</ref><ref>{{cite journal | vauthors = Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW | title = Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology | journal = Neurology | volume = 74 | issue = 18 | pages = 1463–70 | date = May 2010 | pmid = 20439849 | pmc = 2871006 | doi = 10.1212/WNL.0b013e3181dc1ae0 }}</ref>。

====副作用====
[[File:Copaxone_Injection_Site_Reaction.JPG|thumb]]
干擾素及格拉替美（glatiramer）等疾病調節劑最常見的副作用之一是注射處紅腫（皮下注射90%機率，肌肉注射33%機率）<ref name=Balak2012>{{cite journal | vauthors = Balak DM, Hengstman GJ, Çakmak A, Thio HB | title = Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review | journal = Multiple Sclerosis | volume = 18 | issue = 12 | pages = 1705–17 | date = December 2012 | pmid = 22371220 | doi = 10.1177/1352458512438239 }}</ref>。且注射一段時間後，注射處的脂肪組織會崩解，形成一個明顯的凹痕，此現象稱為{{tsl|en|lipoatrophy|脂萎縮|}}（lipoatrophy）<ref name=Balak2012/>。干擾素還可能會造成{{tsl|en|flu-like symptoms|流感類似癥|類似流行性感冒的症狀}}<ref name="pmid17131933">{{cite journal | vauthors = Sládková T, Kostolanský F | title = The role of cytokines in the immune response to influenza A virus infection | journal = Acta Virologica | volume = 50 | issue = 3 | pages = 151–62 | year = 2006 | pmid = 17131933 }}</ref>。有些人注射格拉替美後產生的潮紅、胸悶、心悸，和焦慮，通常這些現象不會持續超過30分鐘<ref>{{cite journal | vauthors = La Mantia L, Munari LM, Lovati R | title = Glatiramer acetate for multiple sclerosis | journal = The Cochrane Database of Systematic Reviews | issue = 5 | pages = CD004678 | date = May 2010 | pmid = 20464733 | doi = 10.1002/14651858.CD004678.pub2 }}</ref>。疾病調節劑還有其他更危險但罕見的副作用，如干擾素有造成{{tsl|en|hepatotoxicity|肝毒性|肝損傷}}的風險<ref name="pmid15592724">{{cite journal | vauthors = Tremlett H, Oger J | title = Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis | journal = Journal of Neurology | volume = 251 | issue = 11 | pages = 1297–303 | date = November 2004 | pmid = 15592724 | doi = 10.1007/s00415-004-0619-5 }}</ref>；[[米托蒽醌|米托蒽醌]]則有可能造成[[心臟衰竭|心臟收縮問題]]（12%）、[[不孕|不孕]]，以及[[急性骨髓性白血病|急性骨髓性白血病]]（0.8%）等問題<ref name=CochMit2013/><ref name="pmid19882365">{{cite journal | vauthors = Comi G | title = Treatment of multiple sclerosis: role of natalizumab | journal = Neurological Sciences | volume = 30 Suppl 2 | issue = S2 | pages = S155-8 | date = October 2009 | pmid = 19882365 | doi = 10.1007/s10072-009-0147-2 | series = 30 }}</ref>；那他珠單抗則有機會造成[[进行性多灶性白质脑病|进行性多灶性白质脑病]]（PML，1/600人）<ref name=Tsang2011/><ref>{{cite journal | vauthors = Hunt D, Giovannoni G | title = Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring | journal = Practical Neurology | volume = 12 | issue = 1 | pages = 25–35 | date = February 2012 | pmid = 22258169 | doi = 10.1136/practneurol-2011-000092 }}</ref>。

{{tsl|en|fingolimod|芬戈莫德|}}（Fingolimod）可能導致[[高血壓|高血壓]]、[[心跳过缓|心率下降]]、[[黃斑水腫|黃斑部水腫]]、肝指數上升，或{{tsl|en|lymphopenia|淋巴球減少症|淋巴球減少}}<ref name="pmid22014437">{{cite journal | vauthors = Killestein J, Rudick RA, Polman CH | title = Oral treatment for multiple sclerosis | journal = The Lancet. Neurology | volume = 10 | issue = 11 | pages = 1026–34 | date = November 2011 | pmid = 22014437 | doi = 10.1016/S1474-4422(11)70228-9 }}</ref>。目前證據傾向支持短期使用芬戈莫德似乎安全，常見副作用包含頭痛、疲倦、惡心、脫髮，和四肢疼痛<ref name=He2016 />。更嚴重的不良反應包含肝衰竭、进行性多灶性白质脑病，以及[[畸形学|致畸性]]都曾有報導<ref name="pmid22014437"/>。{{tsl|en|dimethyl fumarate|富馬酸二甲酯|}}的常見副作用為潮紅和腸胃道副作用<ref name=fumarate/><ref name="pmid22014437"/>。馬酸二甲酯還可能會導致[[嗜中性白血球低下|白血球數量減少]]，但目前試驗並無伺機性感染的報導<ref name=fumarateNDA>{{cite web |title=NDA 204063 – FDA Approved Labeling Text |url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204063lbl.pdf |date=2013-03-27 |access-date=2013-04-05 |publisher=US Food and Drug Agency |deadurl=no |archive-url=https://web.archive.org/web/20131004220910/http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204063lbl.pdf |archive-date=2013-10-04  }}<br>{{cite web |title=NDA Approval |date=2013-03-27 |url=http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/204063Orig1s000ltr.pdf |access-date=2013-04-05 |publisher=US Food and Drug Agency |deadurl=no |archive-url=https://web.archive.org/web/20131004220451/http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/204063Orig1s000ltr.pdf |archive-date=2013-10-04  }}</ref><ref name="pmid22224673"/>。

===相關症狀===
藥物和{{tsl|en|neurorehabilitation|神經復健|}}都可以改善部分症狀，但兩者皆無法逆轉病程<ref name="pmid16168933">{{cite journal | vauthors = Kesselring J, Beer S | title = Symptomatic therapy and neurorehabilitation in multiple sclerosis | journal = The Lancet. Neurology | volume = 4 | issue = 10 | pages = 643–52 | date = October 2005 | pmid = 16168933 | doi = 10.1016/S1474-4422(05)70193-9 }}</ref>。有些症狀如膀胱功能失調和痙攣等症狀對藥物有顯著效果，但其他症狀的效果就相對不佳<ref name="pmid18970977"/>。其他神經學症狀需依賴[[科际整合|科際合作]]來改善病人的生活品質。由於多發性硬化症的病程及醫療涉及多項醫學專科，因此難以界定所謂的「核心團隊」<ref name="pmid18970977"/>。良好的科際整合復健計畫可以增進患者的活動功能（activity）和參與功能（participation），但對改善患者的身體功能損傷沒有助益<ref name="pmid17443610">{{cite journal | vauthors = Khan F, Turner-Stokes L, Ng L, Kilpatrick T | title = Multidisciplinary rehabilitation for adults with multiple sclerosis | journal = The Cochrane Database of Systematic Reviews | issue = 2 | pages = CD006036 | date = April 2007 | pmid = 17443610 | doi = 10.1002/14651858.CD006036.pub2 | editor1-last = Khan | editor1-first = Fary }}</ref>。目前關於個別治療計畫的效果證據有限<ref name="pmid15859525">{{cite journal | vauthors = Steultjens EM, Dekker J, Bouter LM, Leemrijse CJ, van den Ende CH | title = Evidence of the efficacy of occupational therapy in different conditions: an overview of systematic reviews | journal = Clinical Rehabilitation | volume = 19 | issue = 3 | pages = 247–54 | date = May 2005 | pmid = 15859525 | doi = 10.1191/0269215505cr870oa }}</ref><ref name="pmid12917976">{{cite journal | vauthors = Steultjens EM, Dekker J, Bouter LM, Cardol M, Van de Nes JC, Van den Ende CH | title = Occupational therapy for multiple sclerosis | journal = The Cochrane Database of Systematic Reviews | volume =  | issue = 3 | pages = CD003608 | year = 2003 | pmid = 12917976 | doi = 10.1002/14651858.CD003608 | editor1-last = Steultjens | editor1-first = Esther EMJ }}</ref>，但有良好證據顯示運動<ref name="pmid17482708">{{cite journal | vauthors = Gallien P, Nicolas B, Robineau S, Pétrilli S, Houedakor J, Durufle A | title = Physical training and multiple sclerosis | journal = Annales De Readaptation Et De Medecine Physique | volume = 50 | issue = 6 | pages = 373–6, 369–72 | date = July 2007 | pmid = 17482708 | doi = 10.1016/j.annrmp.2007.04.004 }}</ref><ref>{{cite journal | vauthors = Rietberg MB, Brooks D, Uitdehaag BM, Kwakkel G | title = Exercise therapy for multiple sclerosis | journal = The Cochrane Database of Systematic Reviews | issue = 1 | pages = CD003980 | date = January 2005 | pmid = 15674920 | doi = 10.1002/14651858.CD003980.pub2 | editor1-last = Kwakkel | editor1-first = Gert }}</ref>和心理治療對疾病有些幫助<ref>{{cite journal | vauthors = Thomas PW, Thomas S, Hillier C, Galvin K, Baker R | title = Psychological interventions for multiple sclerosis | journal = The Cochrane Database of Systematic Reviews | issue = 1 | pages = CD004431 | date = January 2006 | pmid = 16437487 | doi = 10.1002/14651858.CD004431.pub2 | editor1-last = Thomas | editor1-first = Peter W }}</ref>。[[认知行为疗法|認知行為療法]]則顯示對於多發性硬化症造成的疲憊症狀有所助益<ref>{{cite journal |last1=van den Akker |first1=Lizanne Eva |last2=Beckerman |first2=Heleen |last3=Collette |first3=Emma Hubertine |last4=Eijssen |first4=Isaline Catharine Josephine Maria |last5=Dekker |first5=Joost |last6=de Groot |first6=Vincent |title=Effectiveness of cognitive behavioral therapy for the treatment of fatigue in patients with multiple sclerosis: A systematic review and meta-analysis |journal=Journal of Psychosomatic Research |date=November 2016 |volume=90 |pages=33–42 |doi=10.1016/j.jpsychores.2016.09.002}}</ref>。

===其他療法===
超過50%的多發性硬化症患者會尋求[[替代医学|替代醫療]]（此比率依替代醫療的定義而有差異）<ref name="pmid16420779"/>，但替代醫療的療效通常證據薄弱或缺乏證據支持<ref name="pmid16420779"/><ref name="pmid19222053">{{cite journal | vauthors = Olsen SA | title = A review of complementary and alternative medicine (CAM) by people with multiple sclerosis | journal = Occupational Therapy International | volume = 16 | issue = 1 | pages = 57–70 | year = 2009 | pmid = 19222053 | doi = 10.1002/oti.266 }}</ref>。這些未經驗證的療法包括飲食補充與配方<ref name="pmid16420779"/><ref>{{cite journal | vauthors = Farinotti M, Vacchi L, Simi S, Di Pietrantonj C, Brait L, Filippini G | title = Dietary interventions for multiple sclerosis | journal = The Cochrane Database of Systematic Reviews | volume = 12 | pages = CD004192 | date = December 2012 | pmid = 23235605 | doi = 10.1002/14651858.CD004192.pub3 }}</ref><ref name="pmid21965673">{{cite journal | vauthors = Grigorian A, Araujo L, Naidu NN, Place DJ, Choudhury B, Demetriou M | title = N-acetylglucosamine inhibits T-helper 1 (Th1)/T-helper 17 (Th17) cell responses and treats experimental autoimmune encephalomyelitis | journal = The Journal of Biological Chemistry | volume = 286 | issue = 46 | pages = 40133–41 | date = November 2011 | pmid = 21965673 | pmc = 3220534 | doi = 10.1074/jbc.M111.277814 }}</ref>、維生素D<ref>{{cite journal | vauthors = Pozuelo-Moyano B, Benito-León J, Mitchell AJ, Hernández-Gallego J | title = A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis | journal = Neuroepidemiology | volume = 40 | issue = 3 | pages = 147–53 | year = 2013 | pmid = 23257784 | pmc = 3649517 | doi = 10.1159/000345122 | type = Systematic review | quote = the available evidence substantiates neither clinically significant benefit nor harm from vitamin D in the treatment of patients with MS }}</ref>、[[瑜珈|瑜珈]]等{{tsl|en|relaxation technique|放鬆技巧}}<ref name="pmid16420779"/>、[[草藥醫學|草藥]]（包括[[医用大麻|医用大麻]]）<ref name="pmid16420779"/><ref>{{cite journal | vauthors = Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E | title = Cannabis use in patients with multiple sclerosis | journal = Multiple Sclerosis | volume = 12 | issue = 5 | pages = 646–51 | date = October 2006 | pmid = 17086912 | doi = 10.1177/1352458506070947 }}</ref><ref>{{cite journal |title=Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis A Systematic Review and Meta-analysis |journal=JAMA Network Open |date=2018-10-12 |doi=10.1001/jamanetworkopen.2018.3485}}</ref>、[[高壓氧治療|高壓氧治療]]<ref name="pmid14974004">{{cite journal | vauthors = Bennett M, Heard R | title = Hyperbaric oxygen therapy for multiple sclerosis | journal = The Cochrane Database of Systematic Reviews | issue = 1 | pages = CD003057 | year = 2004 | pmid = 14974004 | doi = 10.1002/14651858.CD003057.pub2 | editor1-last = Bennett | editor1-first = Michael H }}</ref>、{{tsl|en|helminthic therapy|寄生蟲療法|自行吞下鉤蟲}}、[[區域反射療法|區域反射療法]]、[[针灸|针灸]]<ref name="pmid16420779"/><ref>{{cite news | first=Tim | last=Adams | title=Gut instinct: the miracle of the parasitic hookworm | url=https://www.theguardian.com/lifeandstyle/2010/may/23/parasitic-hookworm-jasper-lawrence-tim-adams | newspaper=The Observer | date=2010-05-23 | deadurl=no | archive-url=https://web.archive.org/web/20141024051021/http://www.theguardian.com/lifeandstyle/2010/may/23/parasitic-hookworm-jasper-lawrence-tim-adams | archive-date=2014-10-24 }}</ref>和[[正念療法|正念療法]]<ref>{{Cite journal|last=Simpson|first=Robert|year=2014|title=Mindfulness based interventions in multiple sclerosis – a systematic review|url=http://bmcneurol.biomedcentral.com/articles/10.1186/1471-2377-14-15|journal=BMC Neurology|volume=|pages=|via=|deadurl=no|archive-url=https://web.archive.org/web/20170216051037/http://bmcneurol.biomedcentral.com/articles/10.1186/1471-2377-14-15|archive-date=2017-02-16}}</ref>。採用這些療法的患者以女性、長時間罹病、失能嚴重或對常規醫療滿意度低的患者較多<ref name="pmid16420779"/>。

血管外科醫師{{tsl|en|Paolo Zamboni|保羅·贊博尼|}}在2008年提出了{{tsl|en|chronic cerebrospinal venous insufficiency|慢性腦脊髓靜脈回流不足|}}（CCSVI）假說，認為多發性硬化症和腦部的靜脈狹窄有關。因此推行血管手術試圖改善多發性硬化症。但後來研究發現手術介入並無任何效益<ref name=":0">{{Cite journal|title=Efficacy and Safety of Extracranial Vein Angioplasty in Multiple Sclerosis: A Randomized Clinical Trial|url=https://jamanetwork.com/journals/jamaneurology/fullarticle/2664001|last=Filippini|first=Graziella|last2=Valsecchi|first2=Maria Grazia|date=2018-01-01|journal=JAMA Neurology|issue=1|doi=10.1001/jamaneurol.2017.3825|volume=75|pages=35–43|language=en|issn=2168-6149|last3=Simi|first3=Silvana|last4=D’Amico|first4=Roberto|last5=Papini|first5=Donato|last6=Galeotti|first6=Roberto|last7=Cenni|first7=Patrizia|last8=D’Alessandro|first8=Roberto|last9=Salvi|first9=Fabrizio}}</ref>，且徒增副作用及死亡風險<ref name="pmid20398855">{{cite journal|title=Venous abnormalities and multiple sclerosis: another breakthrough claim?|date=May 2010|journal=The Lancet. Neurology|issue=5|doi=10.1016/S1474-4422(10)70098-3|volume=9|pages=464–5|pmid=20398855|vauthors=Qiu J}}</ref>，因此不建議進行<ref name=":0" />。

==預後==
[[File:Multiple_sclerosis_world_map-DALYs_per_million_persons-WHO2012.svg|thumb]]（每十萬人）
{{refbegin|3}}
{{legend|#ffff20|32-68}}
{{legend|#ffe820|68-75}}
{{legend|#ffd820|77-77}}
{{legend|#ffc020|77-88}}
{{legend|#ffa020|88-105}}
{{legend|#ff9a20|106-118}}
{{legend|#f08015|119-119}}
{{legend|#e06815|120-148}}
{{legend|#d85010|151-462}}
{{legend|#d02010|470-910}}
{{refend}}
]]

多發性硬化症的病程取決於疾病的亞型、個人的性別與年齡、最初的症狀和患者[[身心障礙|失能]]的程度<ref name="pmid8017890"/>。女性、復發緩解型、一開始有視神經炎或感覺症狀、最初幾年較少發作、較早發病的患者有較好的預後<ref name="pmid8017890"/><ref name="pmid3495637">{{cite journal | vauthors = Phadke JG | title = Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in north east Scotland | journal = Journal of Neurology, Neurosurgery, and Psychiatry | volume = 50 | issue = 5 | pages = 523–31 | date = May 1987 | pmid = 3495637 | pmc = 1031962 | doi = 10.1136/jnnp.50.5.523 }}</ref>。

發病後的平均預期餘命為30年，較未得病的群體少了5到10年<ref name="pmid18970977"/>。接近40%的患者能活到七十幾歲<ref name="pmid3495637"/>，但三分之二的死亡直接與此疾病相關<ref name="pmid18970977"/>。患者的[[自殺|自殺]]率也較高，對肢體障礙的患者而言感染和其他併發症的風險則特別高<ref name="pmid18970977"/>。

約有80%的多發性硬化症患者一開始是以臨床單一症候群表現。若核磁共振掃描發現未進犯的神經區域有異常的影像學變化，在未來兩年內有50%的機率會發生脫髓鞘疾病，20年內的機率甚至高達八成<ref>{{Cite journal|title=Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria|author=|url=https://www.ncbi.nlm.nih.gov/pubmed/21387374?dopt=Abstract|last=Polman|first=Chris H.|last2=Reingold|first2=Stephen C.|date=2011-2|journal=Annals of Neurology|issue=2|doi=10.1002/ana.22366|others=|year=|volume=69|page=|pages=292–302|issn=1531-8249|pmc=3084507|pmid=21387374|last3=Banwell|first3=Brenda|last4=Clanet|first4=Michel|last5=Cohen|first5=Jeffrey A.|last6=Filippi|first6=Massimo|last7=Fujihara|first7=Kazuo|last8=Havrdova|first8=Eva|last9=Hutchinson|first9=Michael}}</ref>。約有三成男性且較年輕發病的患者會在54歲時會失去獨立行走的能力<ref>{{Cite journal|title=Age at disability milestones in multiple sclerosis|author=|url=https://academic.oup.com/brain/article/129/3/595/390809|last=Vukusic|first=Sandra|last2=Confavreux|first2=Christian|date=2006-03-01|journal=Brain|issue=3|doi=10.1093/brain/awh714|others=|year=|volume=129|page=|pages=595–605|language=|issn=0006-8950|pmid=}}</ref>。

==流行病學==
[[File:Multiple_sclerosis_world_map-Deaths_per_million_persons-WHO2012.svg|thumb]]
多發性硬化症是最常見的[[中樞神經系統|中樞神經]]自體免疫疾病<ref name="pmid24746689"/>。2017年，全球約有160至195萬名患者（約每10萬人30名）<ref name=Atlas2008/><ref name=Milo2010/>，估計每年造成18,000人死亡<ref name=Loz2012>{{cite journal | vauthors = Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA | display-authors = 6 | title = Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 | journal = Lancet | volume = 380 | issue = 9859 | pages = 2095–128 | date = December 2012 | pmid = 23245604 | doi = 10.1016/S0140-6736(12)61728-0 }}</ref>。個別區域來看，非洲地區的盛行率每10萬人不到0.5人，東南亞每10萬人2.8人，美國每10萬人8.3人，歐洲每10萬人80人<ref name=Atlas2008/>，部分北歐族裔更超過每10萬人200人<ref name=Milo2010/>。全球每年的發生率（新發生個案）則約為每10萬人2.5人<ref name=Atlas2008/>。

多發性硬化症的發生率似乎正在上升，但這或許可以用診斷技術的進步來解釋<ref name=Milo2010/>。近年來，族群研究和地理分布研究越來越普遍<ref name="pmid8269393">{{cite journal | vauthors = Kurtzke JF | title = Epidemiologic evidence for multiple sclerosis as an infection | journal = Clinical Microbiology Reviews | volume = 6 | issue = 4 | pages = 382–427 | date = October 1993 | pmid = 8269393 | pmc = 358295 | doi = 10.1128/CMR.6.4.382 | url = http://cmr.asm.org/cgi/pmidlookup?view=long&pmid=8269393 }}</ref>，科學家也據此相繼提出了一些解釋此現象的理論<ref name="pmid17444504"/><ref name="pmid15556803">{{cite journal | vauthors = Marrie RA | title = Environmental risk factors in multiple sclerosis aetiology | journal = The Lancet. Neurology | volume = 3 | issue = 12 | pages = 709–18 | date = December 2004 | pmid = 15556803 | doi = 10.1016/S1474-4422(04)00933-0 }}</ref><ref name="pmid17492755">{{cite journal | vauthors = Ascherio A, Munger KL | title = Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors | journal = Annals of Neurology | volume = 61 | issue = 6 | pages = 504–13 | date = June 2007 | pmid = 17492755 | doi = 10.1002/ana.21141 }}</ref>。

多發性硬化症常在成年發生，特別是25到35歲，但在少數的情形下也可發生在孩童或大於50歲的人身上<ref name=Atlas2008/><ref name=Milo2010/>，其中50幾歲的人較常見原發進行性多發性硬化症<ref name="pmid17884680"/>。就如同許多其他的自體免疫疾病，多發性硬化症在女性較常見，這樣的趨勢正在增加中<ref name="pmid18970977"/><ref name="pmid18606967">{{cite journal | vauthors = Alonso A, Hernán MA | title = Temporal trends in the incidence of multiple sclerosis: a systematic review | journal = Neurology | volume = 71 | issue = 2 | pages = 129–35 | date = July 2008 | pmid = 18606967 | pmc = 4109189 | doi = 10.1212/01.wnl.0000316802.35974.34 }}</ref>。到2008年為止，女性的發生率約為男性的2倍<ref name=Atlas2008/>；在兒童中，女性的發生率則比男性高出更多<ref name="pmid18970977"/>；但在超過50歲的人口中，男女的發生率則差不多<ref name="pmid17884680"/>。
==歷史==

===發現===
[[Image:Carswell-Multiple_Sclerosis2.jpg|thumb]]級[[脊髓|脊髓]]病灶的描繪。繪於1838年。]]
英國[[病理学|病理學家]]{{tsl|en|Robert Carswell (pathologist)|羅伯特·凱斯威爾 (病理學家)|羅伯特·凱斯威爾}}教授（1793–1857）和法國解剖病理學家{{tsl|en|Jean Cruveilhier|讓·克呂維耶|}}教授（1791–1873）曾描述許多與多發性硬化症症狀類似的疾病細節，但當時他們都尚未把他劃分為獨立診斷<ref name="pmid3066846">{{cite journal | vauthors = Compston A | title = The 150th anniversary of the first depiction of the lesions of multiple sclerosis | journal = Journal of Neurology, Neurosurgery, and Psychiatry | volume = 51 | issue = 10 | pages = 1249–52 | date = October 1988 | pmid = 3066846 | pmc = 1032909 | doi = 10.1136/jnnp.51.10.1249 }}</ref>。凱斯威爾當時以描述這種疾病為「合併萎縮的脊髓病灶」<ref name="pmid18970977"/>。1863年，瑞士病理學家{{tsl|en|Georg Eduard Rindfleisch|喬治·愛德華·林德弗雷奇|}}（1836–1908）在顯微鏡檢下發現沿血管發生的發炎性神經病灶<ref name="pmid10603616">{{cite journal | vauthors = Lassmann H | title = The pathology of multiple sclerosis and its evolution | journal = Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences | volume = 354 | issue = 1390 | pages = 1635–40 | date = October 1999 | pmid = 10603616 | pmc = 1692680 | doi = 10.1098/rstb.1999.0508 }}</ref><ref>{{cite journal|title=Multiple sclerosis pathology: evolution of pathogenetic concepts|date=July 2005|journal=Brain Pathology|issue=3|doi=10.1111/j.1750-3639.2005.tb00523.x|volume=15|pages=217–22|pmid=16196388|vauthors=Lassmann H}}</ref>。

1868年，法國[[神經內科|神經學家]][[让-马丁·沙可|讓-馬丁·沙可]]（1825–1893）在回顧過去文獻，加上自己的臨床和病理觀察後，首次建立多發性硬化症此一診斷<ref name="pmid3066846"/>。

===診斷===

在沙可建立診斷的同時，他也嘗試首度建立多發性硬化症的診斷標準，並提出著名的「沙可三重症」（Charcot Triad）{{Notetag|沙可曾經提過兩個「沙可三重症」，除了文中所說與多發性硬化症有關的三重症之外，還有另一個更常見的用法是描述[[膽囊炎|膽囊炎]]症狀的沙可三重症。}}。所謂沙可三重症包含[[眼球震颤|眼球震顫]]、{{tsl|en|intention tremor|意向性顫抖|}}、{{tsl|en|telegraphic speech|電報式語言|}}等等<ref name="Milo">R. Milo, A. Miller, Revised diagnostic criteria of multiple sclerosis, Autoimmunity Reviews 13 (2014), 12 January 2014, 518–524</ref>。沙可另外還觀察到患者有認知功能改變的問題，他描述病人在記憶功能上有明顯減退，且在概念形成上也比較緩慢<ref name="Charcot1"/>。

自此，沙可三重症成為多發性硬化症的標準診斷依據，直到1965年{{tsl|en|Schumacher criteria|舒馬克診斷標準|舒馬克}}首度提出標準化的診斷標準才逐漸式微。舒馬克導入了散在性病灶、發病時間差，以及「症狀無法以其他解釋」等標準<ref name="Milo"/>。上述幾項新增的內容都為後來的{{tsl|en|Poser criteria|波色診斷標準|}}及現今廣泛使用的{{tsl|en|McDonald criteria|麥克唐納診斷標準|}}所收錄。

到了20世紀，關於此病症病理機轉的理論開始有些進展，到了1990年代之後更發展出了數項治療<ref name="pmid18970977"/>。2010年重新修訂後的麥氏診斷標準容許利用單一病灶進行多發性硬化症的診斷（即臨床單一症後群）<ref name="mcdonald2010">{{cite journal|title=Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria|date=February 2011|journal=Annals of Neurology|issue=2|doi=10.1002/ana.22366|volume=69|pages=292–302|pmc=3084507|pmid=21387374|vauthors=Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS}}</ref>。2013年更將臨床單一症後群列為多發性硬化症的一種表型。自此，不再有「從臨床單一症後群進展為多發性硬化症」的說法存在<ref>{{cite journal|title=Defining the clinical course of multiple sclerosis: the 2013 revisions|date=July 2014|journal=Neurology|issue=3|doi=10.1212/WNL.0000000000000560|volume=83|pages=278–86|pmc=4117366|pmid=24871874|vauthors=Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH}}</ref>。

===歷史病例===
[[File:Animal_locomotion._Plate_541_(Boston_Public_Library).jpg|thumb]]攝，1887年。]]
在沙可建立此診斷之前，相關診斷無法進行。下列病例在重新回顧分析後，可能也是多發性硬化症的患者。

11世紀左右，有一名居住於[[冰島|冰島]]的年輕女性哈朵拉（Halldora）突然失去視力和運動功能，在祈禱之後的七天奇蹟似地恢復。[[斯希丹|斯希丹]]的{{tsl|en|Saint Lidwina|聖李維娜|}}（1380–1433）是一名[[荷蘭|荷蘭]][[修女|修女]]，她可能是目前已知最古老的可診斷病例之一。聖李維娜從16歲到她53歲病逝之間的歲月裡，身受間歇性疼痛、下肢無力、視力喪失等症狀所苦，而上述症狀都是典型多發性硬化症的症狀<ref name="pmid390966">{{cite journal|title=Does the history of multiple sclerosis go back as far as the 14th century?|date=September 1979|journal=Acta Neurologica Scandinavica|issue=3|doi=10.1111/j.1600-0447.1979.tb08970.x|volume=60|pages=189–92|pmid=390966|vauthors=Medaer R}}</ref>。上述的這兩個病例，也使後人提出多發性硬化症可能源自[[維京人|維京人]]的假說<ref name="pmid16479124">{{cite journal | vauthors = Holmøy T | title = A Norse contribution to the history of neurological diseases | journal = European Neurology | volume = 55 | issue = 1 | pages = 57–8 | year = 2006 | pmid = 16479124 | doi = 10.1159/000091431 }}</ref>。

{{tsl|en|Augustus d'Este|奧古斯塔斯·德斯特|奧古斯塔斯·弗德里克·德斯特}}（1794–1848）是{{tsl|en|Prince Augustus Frederick, Duke of Sussex|薩西克斯公爵奧古斯塔斯·腓特烈|}}和{{tsl|en|Lady Augusta Murray|奧古斯塔·穆雷|茉蕊夫人}}之子，同時也是英國國王[[喬治三世|喬治三世]]之孫。德斯特在28歲參加完朋友葬禮之後，出現了{{tsl|en|amaurosis fugax|暫時性黑矇症|短暫性視覺喪失}}的現象。之後他又發生了下肢無力，雙手麻木及動作不協調，膀胱失調，以及[[勃起功能障碍|陰莖不舉]]等等，到了1844年他開始使用輪椅輔助他的行動。儘管疾病纏身，德斯特仍然維持樂觀的態度面對人生。他從1822年到1846年的日記至今仍留存於世，紀載了他22年於疾病共生的生活。詳實的病程紀載，使他幾乎可以直接確診為多發性硬化症<ref>{{cite book|author=Firth D|title=The Case of August D`Esté|year=1948|publisher=Cambridge University Press|location=Cambridge}}</ref><ref name="pmid16103678">{{cite journal|title=Historical descriptions of multiple sclerosis|journal=European Neurology|issue=1|doi=10.1159/000087387|year=2005|volume=54|pages=49–53|pmid=16103678|vauthors=Pearce JM}}</ref>。

英國日記作家布魯斯·弗雷德里克·卡明斯（Bruce Frederick Cummings，1889–1919）以[[筆名|筆名]]「{{tsl|en|W. N. P. Barbellion|W·N·P·巴貝利昂|}}」在他的日記詳實紀載他的病程和他的心路歷程<ref name="pmid16103678" />。他的日記後來於1919年以《{{tsl|en|The Journal of a Disappointed Man|鬱人日誌|}}》（''The Journal of a Disappointed Man''）為書名集結出版<ref>{{cite book|last=Barbellion|first=Wilhelm Nero Pilate|title=The Journal of a Disappointed Man|year=1919|publisher=George H. Doran|location=New York|isbn=0-7012-1906-8}}</ref>。

==研究==
===藥物===
[[Image:Alemtuzumab_Fab_1CE1.png|thumb]]
為多發性硬化症找尋更有效、更安全，及更方便的藥物治療仍是目前研究重點。其他研究方向包含{{tsl|en|neuroprotection|神經保護|}}策略以及症狀治療方針等等<ref name="pmid19597083"/>。

自21世紀以來，有多種口服藥物已經核准上市，用藥也逐漸普及<ref name="pmid21425270">{{cite journal | vauthors = Miller AE | title = Multiple sclerosis: where will we be in 2020? | journal = The Mount Sinai Journal of Medicine, New York | volume = 78 | issue = 2 | pages = 268–79 | year = 2011 | pmid = 21425270 | doi = 10.1002/msj.20242 }}</ref>。目前仍有多種口服藥物仍在開發中，如{{tsl|en|ozanimod|ozanimod|}}、{{tsl|en|laquinimod|拉喹莫德|}}（laquinimod）、[[雌三醇|雌三醇]]。拉喹莫德於2012年8月宣布進行治療多發性硬化症的臨床試驗，目前已在進行第三期試驗，但其二期試驗並未顯示顯著效果<ref>{{cite news|last=Jeffrey|first=susan|title=CONCERTO: A Third Phase 3 Trial for Laquinimod in MS|url=http://www.medscape.com/viewarticle/768902|access-date=2013-05-21|newspaper=Medscape Medical News|date=2012-08-09|deadurl=no|archive-url=https://web.archive.org/web/20120917000704/http://www.medscape.com/viewarticle/768902|archive-date=2012-09-17}}</ref>。除了新藥的開發之外，現有藥物的改良也持續進行中。例如將干擾素β-1a進行{{tsl|en|PEGylation|聚乙二醇高分子修飾|}}（PEGylated），以期用更少劑量達到相同效果<ref name="pmid22201341">{{cite journal | vauthors = Kieseier BC, Calabresi PA | title = PEGylation of interferon-β-1a: a promising strategy in multiple sclerosis | journal = CNS Drugs | volume = 26 | issue = 3 | pages = 205–14 | date = March 2012 | pmid = 22201341 | doi = 10.2165/11596970-000000000-00000 }}</ref><ref name=PEG>{{cite press release|url=http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqId=1777510|title=Biogen Idec Announces Positive Top-Line Results from Phase 3 Study of Peginterferon Beta-1a in Multiple Sclerosis|publisher=Biogen Idec|date=2013-01-24|access-date=2013-05-21|deadurl=yes|archive-url=https://web.archive.org/web/20131004220459/http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqId=1777510|archive-date=2013-10-04}}</ref>。雌三醇是人體自然存在的[[性类固醇|性激素]]，後被發現可能可以治療復發緩解型多發性硬化症，目前已進入第二期試驗<ref>{{cite journal | vauthors = Gold SM, Voskuhl RR | title = Estrogen treatment in multiple sclerosis | journal = Journal of the Neurological Sciences | volume = 286 | issue = 1–2 | pages = 99–103 | date = November 2009 | pmid = 19539954 | doi = 10.1016/j.jns.2009.05.028 | pmc = 2760629 }}</ref><ref>{{Cite journal|last=Voskuhl|first=Rhonda R|last2=Wang|first2=HeJing|last3=Wu|first3=T C Jackson|last4=Sicotte|first4=Nancy L|last5=Nakamura|first5=Kunio|last6=Kurth|first6=Florian|last7=Itoh|first7=Noriko|last8=Bardens|first8=Jenny|last9=Bernard|first9=Jacqueline T|title=Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial|journal=The Lancet Neurology|volume=15|issue=1|pages=35–46|doi=10.1016/s1474-4422(15)00322-1|pmid=26621682|year=2016}}</ref>。



[[单克隆抗体|單株抗體]]的高度選擇性使其成為研究重點之一。截至2012年，已有多種單抗顯示可能有潛力對抗多發性硬化症，如{{tsl|en|alemtuzumab|阿侖單抗|}}（alemtuzumab）、{{tsl|en|daclizumab|達利珠單抗|}}（daclizumab），以及[[利妥昔單抗|利妥昔單抗]]（rituximab）、{{tsl|en|ocrelizumab|ocrelizumab|}}、{{tsl|en|ofatumumab|奧法木單抗|}}（ofatumumab）等抗{{tsl|en|CD20||CD20}}的單株抗體<ref name="pmid22224673">{{cite journal | vauthors = Saidha S, Eckstein C, Calabresi PA | title = New and emerging disease modifying therapies for multiple sclerosis | journal = Annals of the New York Academy of Sciences | volume = 1247 | issue =  | pages = 117–37 | date = January 2012 | pmid = 22224673 | doi = 10.1111/j.1749-6632.2011.06272.x }}</ref>。[[美国食品药品监督管理局|美国食品药品监督管理局]]（FDA）已於2017年3月核准{{tsl|en|ocrelizumab|ocrelizumab|}}用於復發緩解型的治療<ref name="STATapproval" />。但由於單抗具有免疫抑制的效果，所以有伺機性感染的風險<ref name="pmid21425270" />。{{tsl|en|JC virus|JC病毒|}}一種一旦感染即會潛伏於體內的病毒，在潛伏期內因為有免疫系統壓制因此不會出現症狀，但那他珠單抗（natalizumab）的使用可能會使病毒打破潛伏，導致[[进行性多灶性白质脑病|進行性多灶性白質腦病]]（PML）<ref name="pmid21425270" />。因此後來建議在用藥前偵測血液中抗JC病毒抗體的多寡，來評估用藥的安全性<ref name="pmid21425270" />。從上例可以看出，隨著單株抗體在治療多發性硬化症的重要性逐漸上升，發展相關的監測機制也能提升用藥者的安全<ref name="pmid21425270" />。

[[联合疗法|聯合療法]]是指同時使用多種藥物進行治療的策略，其發展與創新也是目前的研究焦點之一<ref name="pmid21111490">{{cite journal | vauthors = Milo R, Panitch H | title = Combination therapy in multiple sclerosis | journal = Journal of Neuroimmunology | volume = 231 | issue = 1–2 | pages = 23–31 | date = February 2011 | pmid = 21111490 | doi = 10.1016/j.jneuroim.2010.10.021 }}</ref>。若加入另一種藥物能夠提升治療效果的總和，則這樣的作用稱為協同作用<ref name="pmid21111490" />。目前已有多種臨床試驗測試聯合療法的效果，但目前為止仍尚未發展出足夠有效的聯合療法<ref name="pmid21111490" />。

疾病初期的神經保護及神經再生的研究也是目前的研究重點之一，如[[干细胞疗法|幹細胞療法]]等等<ref name="pmid23039386">{{cite journal | vauthors = Luessi F, Siffrin V, Zipp F | title = Neurodegeneration in multiple sclerosis: novel treatment strategies | journal = Expert Review of Neurotherapeutics | volume = 12 | issue = 9 | pages = 1061–76; quiz 1077 | date = September 2012 | pmid = 23039386 | doi = 10.1586/ern.12.59 }}</ref>。但目前為止尚未有任何療法能夠有效對抗進行性多發性硬化症。目前有多項藥物正在開發中<ref name="pmid21425270" />。

===生物標記分子===
[[File:Journal.pone.0057573.g005_cropped.png|thumb]]

雖然可以預期近期內多發性硬化症的診斷標準不會改變，但科學家仍持續在尋找能幫助診斷和預測疾病活性的[[生物标记|生物標記分子]]<ref name="pmid21425270"/>，正在研發中的診斷方法包括抗髓鞘抗體、血清和腦脊髓液分析等，但目前都還沒有顯著的進展<ref name="pmid19712003">{{cite journal | vauthors = Harris VK, Sadiq SA | title = Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making | journal = Molecular Diagnosis & Therapy | volume = 13 | issue = 4 | pages = 225–44 | year = 2009 | pmid = 19712003 | doi = 10.1007/BF03256329 }}</ref>。

目前沒有任何檢驗能預測多發性硬化症的預後，一些有潛力的分子包括{{tsl|en|interleukin-6|介白素-6|}}、[[一氧化氮|一氧化氮]]與[[一氧化氮合酶|一氧化氮合成酶]]、[[骨桥蛋白|骨橋蛋白]]和{{tsl|en|fetuin|胎球蛋白|}}-A<ref name="pmid19712003"/>。由於疾病的預後取決於神經元退化的結果，一些神經組織退化時會出現的蛋白質也正被研究，例如{{tsl|en|neurofilament|神經絲|}}、[[tau蛋白|tau蛋白]]和{{tsl|en|N-acetylaspartate|乙醯天門冬胺酸|N-乙醯天門冬胺酸}}<ref name="pmid19712003"/>。此外，研究者也正在尋找能預測患者是否會對藥物有反應的生物標記分子<ref name="pmid19712003"/>。

[[正子斷層照影|正子斷層造影]]（PET）和[[核磁共振成像|核磁共振成像]]（MRI）等神經影像技術的進步帶來了更好的診斷力和預後預測能力，雖然這些進步要實際應用到臨床上往往需要數十年的時間<ref name="pmid21425270"/>。在MRI的部分，數種研究中的技術已證實具實用價值，可逐步導入臨床實務，例如雙反轉回覆序列（DIR）、{{tsl|en|magnetization transfer|磁矩轉移|}}、[[擴散磁振造影|擴散磁振造影]]（DWI）和[[功能性磁共振成像|功能性核磁共振成像]]（fMRI）<ref name="pmid22159052">{{cite journal | vauthors = Filippi M, Rocca MA, De Stefano N, Enzinger C, Fisher E, Horsfield MA, Inglese M, Pelletier D, Comi G | title = Magnetic resonance techniques in multiple sclerosis: the present and the future | journal = Archives of Neurology | volume = 68 | issue = 12 | pages = 1514–20 | date = December 2011 | pmid = 22159052 | doi = 10.1001/archneurol.2011.914 }}</ref>。這些技術相較於現有的技術有更高的專一性，但仍缺乏標準化的檢驗流程和常模數值<ref name="pmid22159052"/>。還有一些仍在開發中的技術，例如能量測周邊巨噬細胞、發炎或神經失能的程度的顯影劑<ref name="pmid22159052"/>，以及能測量鐵沈積量或大腦灌流量的技術<ref name="pmid22159052"/>。同樣地，新的PET[[放射性示踪剂|放射性追蹤劑]]能觀測特定生物反應的變化，例如腦組織發炎、皮質病灶、[[细胞凋亡|細胞凋亡]]或再髓鞘化（remylienation）<ref name="pmid20636368">{{cite journal | vauthors = Kiferle L, Politis M, Muraro PA, Piccini P | title = Positron emission tomography imaging in multiple sclerosis-current status and future applications | journal = European Journal of Neurology | volume = 18 | issue = 2 | pages = 226–31 | date = February 2011 | pmid = 20636368 | doi = 10.1111/j.1468-1331.2010.03154.x }}</ref>。抗{{tsl|en|Kir4.1||Kir4.1}}鉀離子通道抗體也可能和多發性硬化症有關<ref>{{cite journal | vauthors = Methner A, Zipp F | title = Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS | journal = Nature Reviews. Neurology | volume = 9 | issue = 2 | pages = 72–3 | date = February 2013 | pmid = 23338282 | doi = 10.1038/nrneurol.2012.277 }}</ref>。

== 註釋 ==
{{NoteFoot}}

== 參見 ==
* {{tsl|en|List of multiple sclerosis organizations|多發性硬化症組織列表|}}
* {{tsl|en|List of people with multiple sclerosis|多發性硬化症患者列表|}}

== 參考文獻 ==
{{Reflist|2}}

== 外部連結 ==
{{Medical condition classification and resources
 | DiseasesDB = 8412
 | ICD10 = {{ICD10|G|35||g|35}}
 | ICD9 = {{ICD9|340}}
 | OMIM = 126200
 | MedlinePlus = 000737
 | eMedicineSubj = neuro
 | eMedicineTopic = 228
 | eMedicine_mult = {{eMedicine2|oph|179}} {{eMedicine2|emerg|321}} {{eMedicine2|pmr|82}} {{eMedicine2|radio|461}}
 | MeshID = D009103
 | GeneReviewsNBK = NBK1316
 | GeneReviewsName = Overview
}}
{{Commons category|Multiple sclerosis}}
* {{dmoz|Health/Conditions_and_Diseases/Neurological_Disorders/Demyelinating_Diseases/Multiple_Sclerosis/}}
* [http://www.atlasofms.org/ 多發性硬化症流行病學的全球資料分析與比對資料庫]

{{Multiple sclerosis}}
{{Diseases of the nervous system}}
{{Autoimmune diseases}}

{{DEFAULTSORT:Multiple Sclerosis}}
[[Category:病因不明的疾病|Category:病因不明的疾病]]
[[Category:多發性硬化症|Category:多發性硬化症]]
{{Good article}}